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Abstract 
 
 
 Phosphonates represent a small, but potent group of compounds with many useful 
therapeutic properties. FR-900098 is a novel chemotherapeutic agent for the treatment of malaria 
and has been effective in humans and other animals. This compound inhibits 1-deoxy-D-
xylulose-5-phosphate (DXP) reductoisomerase, the second step in the nonmevalonate pathway 
for isoprenoid biosynthesis for many organisms including Plasmodium falciparum, the parasite 
responsible for the most virulent form of the disease. The biosynthetic cluster for FR-900098 has 
recently been cloned from Streptomyces rubellomurinus and heterologously expressed in 
Streptomyces lividans and Escherichia coli. 
 In this work, we sought to obtain complete elucidation of the FR-900098 biosynthetic 
pathway. Detailed biochemical studies with purified enzymes were used to verify each of the 
reactions in the antimalarial biosynthesis. In doing so, we revealed an unprecedented functional 
role for nucleotide conjugation to intermediates within the pathway. We also describe the 
characterization of one of the enzymes involved in FR-900098 biosynthesis, the FAD and 
NADPH dependent N-hydroxylase FrbG. A series of biochemical analyses and the solved crystal 
structure provided insights into the catalytic mechanism, including nucleotide conjugation as a 
recognition mechanism for FrbG activity. 
 A thorough understanding of the FR-900098 biosynthetic pathway also provided a 
platform for directed biosynthesis to generate novel derivatives of the compound and metabolic 
engineering in E. coli to increase production of the antimalarial. Although not required for FR-
900098 biosynthesis, the Fe(II) and α-ketoglutarate dependent hydroxylase FrbJ was determined 
to be involved in the synthesis of another phosphonate antibiotic FR-33289. We demonstrated its 
ability to catalyze the hydroxylation of additional substrates as part of the creation of a new 
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library of potential antimalarial compounds. Through a series of bioassays and in vitro 
experiments, we identified two new prospective antimalarials. Metabolic engineering to increase 
FR-900098 production in E. coli was approached in two ways, the first of which was the targeted 
increase of phosphoenolpyruvate (PEP) concentration within the cell. This metabolite is a 
common precursor of phosphonates and is also involved in several reactions of primary 
metabolism. The second approach was to balance flux through the FR-900098 biosynthetic 
pathway through ribosome binding site (rbs) engineering. 
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Chapter 1: Natural Product Biosynthesis and Synthetic Biology 
 
 
1.1 Natural Product Biosynthesis 
 
 Many microorganisms have evolved to produce a diverse group of compounds known as 
natural products or secondary metabolites
1-2
. Natural products contain a very complex 
architecture and rich functionality which undoubtedly result in their high potency and selectivity, 
making them attractive drug candidates
3
. It has been estimated that 75% of drugs used in the 
treatment of severe or life-threatening conditions were of either natural product origin or 
inspiration
4
. Advances in molecular biology, genomics, and proteomics have allowed for the 
rapid discovery of the biosynthetic pathways that synthesize natural products
5
. Unfortunately, 
natural product sources are generally poorly characterized and difficult to grow under standard 
laboratory conditions, making manipulation of the pathways, translation to rapid high throughput 
screening (HTS), and large scale industrial production increasingly difficult
6
. 
 Organic synthesis has been used extensively in partial or total synthesis of natural 
product drugs
7
. Although these traditional methodologies have proven successful in many cases, 
they often lack the high specificity and yields of enzymes. In addition, most organic syntheses 
are not environmentally friendly, requiring the use of heavy metals, organic solvents, and strong 
acids or bases. Many natural products are too structurally complex to be synthesized by organic 
synthetic routes, whereas natural biosynthetic pathways for these compounds already exist
8
. 
Industrial enzymes, predominantly hydrolytic in action, have been utilized in the textile, pulp and 
paper, and detergent industries, among others
9
. Similarly, the pharmaceutical industry has begun 
to incorporate one or more enzymes from natural product pathways for transformations that 
would otherwise be difficult or impossible to achieve by chemical synthesis. The production of 
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natural products in vivo using full biosynthetic pathways, in either the native or heterologous 
host, represents a complementary approach to organic synthesis. 
 
1.1.1 Heterologous Production of Natural Products 
 Direct extraction and purification of natural products from their native producers would 
be the most desirable approach, but these microorganisms are not typically cultivatable in the 
laboratory. Additionally, most native producers grow very slowly, resulting in minute amounts 
of target compound production and an increasing risk of contamination. It has been estimated 
that only 1% of bacteria and 5% of fungi have been cultivated in the laboratory
10-13
. Even when it 
is possible to cultivate the native producer in the laboratory, extensive optimization of growth 
conditions must be completed, which often consumes valuable time and resources. Also, the 
genetic tools to manipulate these complex hosts are severely limited, making the improvement of 
natural product yields difficult. 
 Therefore, a well-characterized microorganism that can be used as a platform for natural 
product biosynthesis is highly desired. This approach focuses on transferring the genetic 
machinery required for natural product biosynthesis from the native producer to a well-
characterized heterologous host, such as Escherichia coli and Saccharomyces cerevisiae. These 
two organisms have become the best options due to the completeness and availability of genetic 
information as well as the feasibility of applying recombinant genetic tools to these systems. The 
utilization of heterologous hosts as a platform for natural product biosynthesis has been 
demonstrated for a wide variety of compounds including polyketides
14-16
, flavanoids
17-18
, 
carotenoids
19-21
, stilbene polyketides
22
, the steroid hydrocortisone
23
, the terpenoid 
amorphadiene
24
 and its derivative artemisinic acid
25-26
. 
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 Several concerns accompany the use of heterologous hosts for the production of natural 
products. First, poor protein expression may arise resulting in inclusion body formation, 
increased amino acid misincorporation, and incomplete posttranslational modification
27
. With 
recent advances in genomics, the codon usage for both the native and heterologous hosts can be 
identified, resulting in codon optimized genes for increased protein expression
3
. Second, the 
substrate pool required in the biosynthesis of certain natural products may not be sufficient in the 
heterologous host, requiring either the inclusion of substrates directly to the production media or 
the coexpression of additional pathways capable of synthesizing these substrates. Using 
heterologous hosts that do not originally have these substrates would also ensure a reduction in 
the amount of side reactions compared to native producers, potentially leading to higher yields of 
the desired compounds
28
. Third, self-resistance to bioactive natural products must also be 
addressed when using heterologous hosts, as there may be growth inhibition upon formation of 
the desired compounds. Fortunately, the self-resistance genes are typically located within the 
same gene cluster in the native producer as the biosynthetic genes, making coexpression an easy 
solution
29-31
. Advances in synthetic biology have allowed for the expansion of heterologous hosts 
as platform organisms, and the success of the mentioned examples provides hope for the cost-
effective production of natural products and in particular, those with carbon-phosphorus bonds. 
 
1.1.2 Natural Products Containing Carbon-Phosphorus Bonds 
 Phosphonates and phosphinates represent a potent, yet underexploited, class of bioactive 
compounds, many of which have therapeutic properties
32
. This group of natural products contain 
a characteristic carbon-phosphorus bond (C-P in phosphonates and C-P-C in phosphinates)
33-34
. 
The C-P bond is highly stabile and can sustain harsh chemical treatments, such as boiling in 
strong acid or base
35
. The bioactivity of these compounds stems from the ability of this bond to 
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actively mimic phosphate esters or carboxylic acids, acting as potent enzyme inhibitors. They 
compete with structurally analogous compounds and bind in the active site of enzymes, yet 
cannot be turned over in many cases due to the chemical inertness of the C-P bond. Interestingly, 
the phosphonate fosfomycin contains functional groups that react with the target enzyme causing 
irreversible inhibition
36
. Phosphonates and phosphinates exhibit desirable bioactivity if the target 
enzyme is within an essential pathway of primary metabolism for a target organism that is absent 
in humans. 
 The first natural compound containing a C-P bond, 2-aminoethylphosphonate (AEP), was 
discovered in Tetrahymena pyriformis
37
. Since its discovery, biosynthetic pathways for 
phosphonates and phosphinates had been found in a wide variety of microorganisms. The final 
compounds can be large macromolecules such as lipids, exopolysaccharides, and glyoproteins as 
well as small, bioactive compounds
34
. The prevalence of C-P compounds in nature is perhaps 
best illustrated by the recent discovery that as much as 20-30% of the available phosphorus in the 
ocean is comprised of phosphonic acids
38
. Most of the known phosphonate antibiotics are 
produced by the Gram-positive soil-dwelling bacteria Streptomyces. It has been estimated that 
approximately 99% of this bacterial species has yet to be fully explored, meaning the potential 
for discovering more bioactive compounds is very high
39
. Many strains of Streptomyces were 
originally believed to be unculturable, but recent attempts using culture-independent molecular 
methods have since shown that a majority are in fact culturable
40-42
. Additionally, the genome of 
Streptomyces coelicolor was recently sequenced and published
43
. After decades of study, four 
novel secondary metabolites produced by S. coelicolor were identified under laboratory 
conditions, but the genome suggests that up to 20 different metabolites could be potentially 
 5 
produced
44
. This suggests that Streptomyces will continue to be a rich source for discovering 
compounds containing C-P bonds and natural products in general. 
 Several representative naturally occurring phosphonates and phosphinates are shown in 
Figure 1.1. The phosphonotripeptide K-26 can be used to lower blood pressure as an angiotensin 
converting enzyme (ACE) inhibitor
45-46
. Phosphonothricin tripeptide (PTT)
47
 and 
phosphonothrixin
48
 are potent herbicides. Fosmidomycin
49
 and FR-900098
50
 represent a new 
class of effective antimalarial compounds
51-53
. Fosfomycin, originally phosphonomycin, is a 
clinically used broad-range antibacterial and is the only FDA approved drug for treatment of 
acute cystitis during pregnancy
54-56
. Finally, a series of rhizocticins are effective antifungals
57
. 
Studying the biosynthetic mechanism for phosphonate and phosphinate production will help 
unlock new biochemistry, discover additional compounds, and assist in the modification and 
improvement of the efficacy and yield of known compounds through synthetic biology. 
 
 
 
 
Figure 1.1 Chemical structures of naturally occurring phosphonates. 
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1.2 Synthetic Biology 
 
 The term synthetic biology was first coined in the late 1970s when it was used to describe 
the application of recombinant DNA technology as a means to construct and evaluate new gene 
arrangements in engineered bacteria
58-59
. Synthetic biology has more recently described a field 
that combines traditional molecular biology and chemistry with engineering in the design and 
synthesis of complex, biologically based systems that do not exist in nature
60-63
. The fundamental 
idea of this field is that any biological system, regardless of the complexity, can be broken down 
into simple, interconnecting elements
64
. The goal is to then modify an organism by harnessing 
the properties of the central dogma of biology; developing an entirely new, more 
biotechnologically relevant system by engineering on the most basic RNA and DNA levels
65-66
. 
 Synthetic biology has been successful in a broad range of applications, scaling in size and 
complexity from the synthesis of proteins containing unnatural amino acids to the construction of 
entirely new organisms with modified genomes. Except for the rare selenocysteine and 
pyrrolysine, the same twenty amino acids comprise all naturally produced proteins
67
. The Schultz 
laboratory established a platform to expand the number of genetically encoded amino acids by 
generating an orthogonal transfer RNA/aminoacyl-tRNA synthetase. This approach has allowed 
for the introduction of unnatural amino acids with novel structural, chemical, and physical 
properties not found among the common amino acids. To date, more than 80 unnatural amino 
acids have been incorporated in proteins expressed in E. coli, yeast, and mammalian cells
68-71
. 
On the opposite end of the spectrum, several examples of full genome cloning have been 
reported. These include the combination of the Synechocystis PCC6803 genome with the 
Bacillus subtilis 168 genome
72
 and the cloning of the mouse mitochondrial genome using a B. 
subtilis genome vector
73
. 
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 The increase in availability and amount of genetic information has been critical towards 
the advancement of synthetic biology. Sequence data from over 165,000 organisms, including 
nearly 400 whole genomes, are readily accessible online at NCBI Genbank. In particular, 
genomics can begin to expose the biosynthetic potential hidden in cryptic and unexpressed 
operons
74
. At the same time, there have been increasing efforts towards the creation of new 
platforms aimed at cloning and transferring large DNA fragments, making manipulation of these 
individual genetic components possible
75-77
. A combination of new synthetic biology tools and 
methods will give rise to the widespread engineering of tailored hosts which are designed to 
produce natural products at higher and more industrially practical levels, as well as create 
entirely new compounds. 
 
1.2.1 Combinatorial Biosynthesis 
Combinatorial biosynthesis refers to the genetic engineering of natural product 
biosynthesis in order to obtain new compounds
78
. Natural products are an excellent starting point 
for combinatorial biosynthesis since they have already been selected through evolution as a way 
for their native producers to gain an advantage in the environment
79
. Evolution has chosen the 
secondary metabolites which best balance the energy cost of production and the physiological or 
ecological benefit. These benefits can be in the form of defense compounds which help ward off 
predators or signaling compounds which attract other organisms
80
. Also, natural products are 
likely to have already evolved to be capable of cell membrane penetration, allowing the 
interaction with specific targets within the cell
81
. Combinatorial biosynthesis enables the 
enormous biodiversity present in nature to be fully accessed by combining genes that would 
never get the chance to meet under natural conditions. Manipulation of the genetic machinery 
may deliver compounds that would not be under evolutionary stress by the influence of selection 
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pressures, habitat, or biochemical limitations
79
. Successful applications of combinatorial 
biosynthesis include, but are certainly not limited to, the synthesis of polyketides and 
carotenoids. 
 The macrolide antibiotic erythromycin, along with several other polyketide antibiotics, is 
important in both medicine and animal health
82
. The polyketide synthase 6-deoxyerythronolide B 
synthase (DEBS) from Saccharopolyspora erythraea is responsible for the macrolide ring 
formation of the precursor for the final compound. DEBS has been extensively studied for the 
generation of erythromycin derivatives through the use of combinatorial biosynthesis. In 
particular, the effects of gene inactivation, domain swaps, and modification to tailoring enzymes 
responsible for the aglycon, glycosylation, or methylation patterns have been investigated
83-86
. 
The study of polyketide synthases similar to DEBS has the advantage of the inherent modularity 
of this class of enzyme. Although substrate recognition of downstream enzymes can become 
disrupted, methods for creating polyketide combinatorial libraries are relatively well-established. 
 Carotenoids are naturally occurring pigments which protect against oxidative damage by 
quenching photosensitizers, interacting with single oxygen molecules, and scavenging peroxy 
radicals
87-88
. These compounds may play an important role in the prevention of cardiovascular 
diseases and cancer and have estimated annual sales of $500 million
89-91
. One example of 
combinatorial biosynthesis of carotenoid biosynthetic pathways was completed by the Arnold 
laboratory. The specificity of C30 carotenoid synthase CrtM was evolved through protein 
engineering to accept substrates containing backbones of sizes C40 and C50. As a result, a series 
of novel carotenoids was synthesized in E. coli when the mutant CrtM was coexpressed with 
modifying enzymes from the naturally occurring pathway
92
. 
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 The core structures of natural products have served as scaffolds for the development of a 
significant number of approved drugs and drug candidates over the past decades
93
. These 
“privileged structures” have become the basis for efforts in combinatorial biosynthesis, 
generating compounds with increased efficacy or even entirely new biological activity
94
. Natural 
product biosynthetic pathways can be altered either by the introduction of elements from other 
pathways, including those from completely different microorganisms, or engineering of the 
pathway itself, namely through protein engineering. Combinatorial biosynthesis is a very 
powerful method to identify novel natural products; however, low yields of the final compound 
must be addressed if it shows promise as a therapeutic drug. In particular, production levels must 
meet industrial standards for scaled up fermentations in pharmaceutical drug formulations. As a 
result, most of these biosynthetic pathways, both natural and those engineered through 
combinatorial biosynthesis, require additional metabolic engineering to increase production 
levels of the final compounds. 
 
1.2.2 Metabolic Engineering 
 
 Metabolic engineering first emerged in the late 1980s and early 1990s with the aim of 
rationally designing metabolic pathways within cells using genetic manipulations
95-96
. Since that 
time, the field has taken substantial strides and is now commonly used in academic research and 
industrial practice. Through the modification of specific biochemical reactions or the 
introduction of new ones through recombinant DNA technology, a single microorganism can 
convert simple carbon sources such as glucose or cellulosic biomass into specialty chemicals, 
bulk chemicals, drugs, and biofuels
97
. This area is particularly important to biotechnology 
because it improves current bioprocesses and provides access to novel products through the 
development of new bioprocesses. 
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 Simply put, the goal of metabolic engineering is to channel carbon flow in the production 
host to the desired product at a high yield; although, there are many considerations that must be 
made during its design and implementation. The first task is introducing the biosynthetic genes 
within the host and the careful balancing between the expression and activity of each. This 
ensures that no gene is drastically overexpressed, which would deprive the cells of valuable 
precursors and cofactors required for growth. Likewise, no gene must be underexpressed, which 
would create a bottleneck in the biosynthetic pathway and limit the overall yield of the desired 
product
98
. Balanced flux throughout the biosynthetic pathway also prevents the build up of toxic 
intermediates and side-products
99
. Second, metabolic engineering requires the maintenance of 
endogenous pathways in the production host. Competing branch pathways must be genetically 
blocked and those which increase the intracellular amount of required precursors and substrates 
must be genetically enhanced
100
. The final aspect that must be addressed is the engineering of the  
cellular regulatory network which combines transcription (mRNA degradation and induction-
repression mechanisms), translation (protein activation and proteolysis), and enzyme activity 
(allostery) in complex signaling cascades
101
. 
 The recent growth of metabolic engineering was made possible by the development of 
new tools in molecular biology, biochemistry, and genetics
102
. For example, expression plasmid 
vectors have been designed for multiple heterologous hosts. Although invaluable for the 
expression of biosynthetic pathways, plasmids suffer from genetic instability and result in 
production loss
103
. In order to reduce the reliance on plasmid-based expression systems, 
engineered pathways are typically transferred onto the chromosome of the production host
104
. 
Genome scale modeling has also been developed for the metabolic pathways in many important 
microorganisms. These models provide targets for deletions and overexpressions of genes within 
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primary metabolism that will improve the flow of substrates and energy into the desired 
pathway. More importantly, they guide metabolic engineers to distal targets for modifications 
that would have otherwise been impossible identify through standard methods
105
. Finally, a 
number of analytical tools have been vital to the development of metabolic engineering. A 
combination of techniques such as liquid chromatography-mass spectrometry (LC-MS), gas 
chromatography-mass spectrometry (GC-MS), nuclear magnetic resonance (NMR), two-
dimensional gel electrophoresis, and DNA microarrays can accurately determine the fluxes of 
DNA, proteins, and metabolites within the cell. 
 One of the quintessential applications of metabolic engineering was the production of 
1,3-propanediol, a specialty chemical and copolymer with high production costs via chemical 
synthesis
106
. Early engineering efforts were aimed at the natural producers of the compound 
including species of Citrobacter, Clostridium, Enterobacter, Klebsiella, and Lactobacillus. 
However, feeding these bacteria the feedstock glycerol and growing them anaerobically resulted 
in the generation of excess reduced nicotinamide adenine dinucleotide (NADH). Nonproducing 
strains of E. coli were targeted for heterologous production of 1,3-propanediol utilizing glucose 
as a feedstock instead. Extensive remodeling of primary metabolism was completed including 
the introduction of genes from S. cerevisiae to divert dihydroxyacetone phosphate from 
glycolysis to glycerol, and genes from Klebsiella pneumoniae were expressed to convert this 
compound to the final product. Further optimization of carbon flow in the organism resulted in a 
strain that could produce 1,3-propanediol at a titer of 135 g L
-1
 (Figure 1.2). The industrialization 
of this process was achieved by DuPont and Genencor for annual production of 50,000 tons
107
. 
The case of 1,3-propanediol, along with other published examples, demonstrates the potential 
power of this field. Metabolic engineering has the capability to provide optimized 
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microorganisms with improved productivity and efficiency for economical industrial 
bioprocesses. 
 
 
 
 
Figure 1.2 Engineered pathway in E. coli for the production of 1,3-propanediol. Genes were cloned from 
S. cerevisiae (green) and K. pneumoniae (red). The gene dhaT encoding the 1,3-propanediol 
oxidoreductase from K. pneumoniae was originally included in the pathway, but an endogenous E. coli 
oxidoreductase yqhD (blue) provided higher titers of the final product. DHAP, dihydroxyacetone 
phosphate; GAP, glyceraldehyde 3-phosphate; tpi, triosephosphate isomerase; gap, glyceraldehyde 
phosphate dehydrogenase; DAR1, glycerol-3-phosphate dehydrogenase; GPP2, glycerol-3-phosphatase; 
dhaB1-3, glycerol dehydratase. This figure was adapted from Nakamura et al.
107
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1.3 Project Overview 
 
 My research focused on the pathway characterization and engineering of the antimalarial 
drug FR-900098. Heterologous production of the compound has been achieved in Streptomyces 
lividans and Escherichia coli. However, many of the biosynthetic steps were proposed based 
only on sequence homology of the genes, without any definitive assignment of the order or 
function. The initial goal was to obtain a complete understanding of the FR-900098 biosynthetic 
pathway. This would open the possibilities for metabolic engineering in the native or 
heterologous Streptomyces strain or in E. coli to increase production of the antibiotic and 
directed biosynthesis to generate novel derivatives of FR-900098. 
 Chapter 2 describes the elucidation of each step required in FR-900098 biosynthesis. The 
initial step in FR-900098 biosynthesis is similar to almost all other known phosphonate 
biosyntheses, a phosphoenolpyruvate (PEP) mutase catalyzed reaction of PEP to 
phosphonopyruvate. The subsequent steps of FR-900098 biosynthesis parallel the tricarboxylic 
(TCA) cycle, resulting in the formation of 2-oxo-4-phosphonobutyrate (2OPn), an analog of α-
ketoglutarate. Whole cell feeding assays with enzymes believed to be involved in the late steps 
of the pathway revealed a series of intermediates conjugated to cytidine 5’-monophosphate 
(CMP). Detailed biochemical studies with purified enzymes were used to verify each of the 
intermediates and reactions in the biosynthesis of the antimalarial FR-900098. 
 Chapter 3 describes the expression, purification, and biochemical characterization of the 
NADPH and FAD dependent N-hydroxylase FrbG. Structural analysis from Professor Satish 
Nair’s laboratory at the University of Illinois revealed there was no room for the CMP-5’-3APn 
substrate in the binding pocket of FrbG providing evidence that the substrate and NADPH 
cofactor might bind alternatively. This was further confirmed by kinetic analysis of the enzyme 
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where substrate inhibition was monitored. Spectroscopic and mutational analysis of FrbG also 
provided insights in the catalytic mechanism of the enzyme including slow binding of NADPH 
and molecular oxygen only being able to enter the active site after NADP
+
 has been displaced 
and CMP-5’-3APn is present. 
 Chapter 4 describes the expression, purification, and biochemical characterization of the 
Fe(II) and α-ketoglutarate dependent hydroxylase FrbJ. Although not required for FR-900098 
biosynthesis, this enzyme was determined to be involved in the synthesis of another phosphonate 
antibiotic FR-33289. We also demonstrated the ability of FrbJ to catalyze the hydroxylation of 
additional substrates as part of the creation of a new library of potential antimalarial drugs. The 
library included a series of phosphonate esters, synthesized by DhpI, an S-adenosyl-L-
methionine (SAM) dependent O-methyltransferase from the dehydrophos cluster. All compounds 
were evaluated for antimalarial activity by bioassay of an E. coli phosphonate uptake strains and 
in vitro inhibition of purified Plasmodium falciparum Dxr (pfDxr). These screens allowed for the 
identification of two new prospective antimalarial compounds. 
 Chapter 5 describes efforts in metabolic engineering to increase FR-900098 production in 
E. coli. One approach was the targeted increase of PEP concentration within the cell. This 
metabolite is a common precursor of phosphonates and is also involved in several reactions of 
primary metabolism. Strategies used to improve the PEP level in E. coli include overexpression 
of Pck (PEP carboxykinase) and Pps (PEP synthase); each enzyme produces PEP from other 
central metabolites. A regulatory protein which represses formation of both enzymes was 
targeted for deletion from the chromosome of the E. coli production strain. The second approach 
to increase FR-900098 production was to balance flux through the biosynthetic pathway itself. 
The ribosome binding site of four IPTG-inducible promoters (Lac, T7, Tac, and Trc) was 
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mutagenized, resulting in a library of promoter strengths. When combined with the FR-900098 
biosynthetic genes, the resulting pathway library can be screened for increased production of the 
antimalarial compound. 
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Chapter 2: Biosynthetic Steps for FR-900098 Production 
 
 
2.1 Introduction 
 
 FR-900098 (3-(N-acetyl-N-hydroxyamino)propylphosphonic acid) is a phosphonate 
antibiotic originally isolated from a soil sample by the Fujisawa Pharmaceutical Corporation 
(Osaka, Japan) in the late 1970s.  The compound is produced by Streptomyces rubellomurinus 
ATCC
®
 31215
™
 and Streptomyces rubellomurinus subsp. indigoferus ATCC
®
 31304
™
 and it 
exhibits a broad spectrum of antimicrobial activity against Gram-negative bacteria and low 
toxicity in experimental animals
1
. Subsequent studies demonstrated that FR-900098 and the 
structurally similar fosmidomycin (FR-31564)
2
 act as very potent inhibitors of 1-deoxy-D-
xylulose-5-phosphate (DXP) reductoisomerase, the second step in the nonmevalonate pathway 
for isoprenoid biosynthesis
3-4
. Both phosphonate compounds are structurally similar to the 
natural substrate of the enzyme and effectively bind to the active site in a slow, tight binding 
mode of inhibition
5
. Genomic analyses indicate that the genes encoding the nonmevalonate 
pathway are present in a wide variety of Gram-negative and Gram-positive bacteria, plants, and 
the parasite causing the most virulent form of malaria, Plasmodium falciparum
6-7
. Mammals 
produce isoprenoids via the mevalonate pathway; therefore, FR-900098 and fosmidomycin 
should not be detrimental to humans
8
. As a result, these two phosphonates represent a novel class 
of antimalarial drugs. 
 Malaria remains one of the most common life-threatening infections in developing 
countries with up to 500 million infections and between one to three millions deaths per year
9
. 
Current antimalarial treatments include chloroquine and sulfadoxin pyrimethamine, but the rapid 
emergence of antibiotic resistance strains is rendering these current therapies futile, creating an 
urgent need for new, effective drugs
10-11
. Early studies revealed that FR-900098 is actually twice 
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more effective than fosmidomycin against strains of Plasmodium falciparum in vitro and the 
closely related Plasmodium vinckei in mice
12-13
. Both FR-900098 and fosmidomycin are 
currently undergoing clinical trials as potential antimalarial drug candidates
14
. Initial clinical 
trials performed in Gabon and Thailand demonstrated the safety and effectiveness of malaria 
treatment with fosmidomycin, although recrudescent infection was observed in some cases
15-16
. 
More recently, a regiment consisting of fosmidomycin and clindamycin resulted in cure rates of 
100% after 14 days in African children
17-18
. These preliminary studies indicate that both FR-
900098 and fosmidomycin will be useful as antimalarial treatments. Progress has been made in 
the development of chemical routes for the synthesis of fosmidomycin
19
 and FR-900098
19-20
, but 
these remain inefficient and costly.  A biological route for the synthesis of FR-900098 should 
provide an inexpensive way to produce the compound, so that the drug can be supplied in large 
quantities to developing countries where malaria remains most prevalent. 
 The Metcalf group utilized a PCR-based approach to identify and cloned the entire FR-
900098 biosynthetic cluster from Streptomyces rubellomurinus ATCC
®
 31215
™
. All known 
phosphonate biosynthetic clusters begin with a phosphoenolpyruvate (PEP) mutase step in which 
PEP is rearranged to phosphonopyruvate
21
. Degenerate primers were designed to anneal to 
conserved regions within homologous genes and a 406 bp fragment was amplified. A large insert 
fosmid library was constructed from the S. rubellomurinus chromosomal DNA and the resulting 
clones were screened by PCR for the presence of the PEP mutase gene. One of them (designated 
4G7) was able to heterologously produce FR-900098 when transferred to the chromosome of S. 
lividans, indicating that all the genes required for biosynthesis were present
22
. However, the 
concentration of FR-900098 produced from the heterologous S. lividans host was approximately 
1 mg L
-1
, which is far too low for any practical applications.  In addition, S. lividans has a 
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complex morphology, grows slowly, and the tools for metabolic engineering of this host are 
rather limited.  E. coli would be a more attractive production host than Streptomyces for several 
reasons.  For example, there are a number of genetic engineering tools readily available, it grows 
very rapidly with a doubling time as short as twenty minutes, and the physiology and 
fermentation conditions for E. coli are already well established. 
 
 
 
Figure 2.1 (A) FR-900098 biosynthetic gene cluster. (B) Proposed biosynthetic pathway for FR-900098 
production. Intermediates are as follows: I, phosphoenolpyruvate; II, phosphonopyruvate; III, 2-
phosphonomethylmalate; IV, 3-phosphonomethylmalate; V, 2-oxo-4-phosphonobutryate; VI, 2-amino-4-
phosphonobutyrate; VII, 3-aminopropylphosphonate; VIII, N-hydroxy-3-aminopropylphosphonate. IX, 
N-acetyl-3-aminopropylphosphonate. This figure was adapted from Eliot et al.
22
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In order to achieve heterologous production of FR-900098 in E. coli, each of the genes in 
the biosynthetic gene cluster were first checked for soluble expression inside of the new host by 
Dr. Tyler Johannes. The eleven genes were cloned, expressed, and then analyzed by SDS-PAGE 
and Western blot. All of the proteins had high expression and showed clear overexpression bands 
in E. coli, except for FrbE which demonstrated low levels of soluble expression detected only by 
Western blot analysis (data not shown). In order to reconstitute the FR-900098 biosynthetic 
pathway in E. coli, each of the eleven genes in the biosynthetic cluster were cloned into a set of 
three compatible Duet expression vectors (pETDuet, pRSFDuet and pACYCDuet). Each 
individual gene is under the transcriptional control of a strong T7 promoter and expression is 
inducible by the addition of isopropyl-β-D-thiogalactopyranoside (IPTG). The constructed 
plasmids were transformed into the heterologous host E. coli to create the production strain
23
. 
The production of FR-900098 was confirmed using liquid chromatography-mass spectrometry 
(LC-MS) analysis as described in Eliot et al.
22
 
 Deletion analysis was utilized to determine the minimal number of genes required for 
heterologous production of FR-900098. Different strains of E. coli were created which lacked a 
single gene from the pathway and each was tested for its ability to produce the final compound. 
The strain lacking dxrB, a homolog of the target enzyme, grew very slowly upon protein 
induction and although the strain eventually grew to saturation, it produced significantly lower 
amounts of FR-900098. This provided evidence for the necessary inclusion of the dxrB gene in 
E. coli production strains as a means of resistance from the increasing concentrations of FR-
900098. The genes frbI and frbJ were not essential for FR-900098 production in E. coli, as the 
compound was still able to be produced in their absence. The final production strain (pETDuet-
frbABCD, pRSFDuet-frbHFG, pACYCDuet-frbE-dxrB) did not include frbI or frbJ, resulting in 
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the highest production of FR-900098, 6.3 mg L
-1
 (Figure 2.2). This was the first known 
heterologous production of a phosphonate antibiotic in E. coli
23
. This chapter will focus on the 
elucidation and biochemical characterization of each step in FR-900098 biosynthetic pathway. 
 
 
Figure 2.2 Heterologous production of FR-900098 in E. coli. (A) Scheme for the three-plasmid system in 
the FR-900098-producing strain. Each gene is under transcriptional control by strong T7 promoter as 
indicated by arrows. (B) Time course production of FR-900098 in E. coli. This figure was reprinted with 
permission from Elsevier Journals. Copyright © Chemistry and Biology, 17, 57-64 (2010). 
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2.2 Results 
 
2.2.1 PEP Mutase Activity of FrbD and Citrate Synthase Activity of FrbC 
 
 The initial step in FR-900098 biosynthesis was presumed to be the phosphoenolpyruvate 
(PEP) mutase catalyzed formation of phosphonopyruvate (PnPy) from PEP. This step is common 
in all known phosphonate biosyntheses and is where the characteristic carbon-phosphorus (C-P) 
is installed. The PEP mutase reaction is highly unfavorable with equilibrium of greater than 
500:1 in favor of PEP, so the second step must serve as a thermodynamic driving force to 
overcome the first step
24-25
. In the three known phosphonate biosynthetic pathways 
(aminoethylphosphonate
26
, fosfomycin
27-28
  and phosphinothricin tripeptide
29-30
), the second step 
is an irreversible thiamine pyrophosphate-dependent decarboxylation of PnPy to form 
phosphonoacetyaldehyde (PnAA). Interestingly, there was no gene present in the cluster 
encoding a PnPy decarboxylase, so there must be a different route to drive the FR-900098 
pathway forward. Several other putative genes in the cluster (frbA, frbB, frbC, and frbE) encode 
enzymes homologous to those in the TCA cycle. Considering that PnPy is a structural analog of 
oxaloacetate, it was proposed that the second and driving step in FR-900098 biosynthesis was 
the citrate synthase homolog FrbC
22
. 
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Figure 2.3 Enzymatic activity of the coupled FrbD and FrbC reactions was measured with the inclusion 
of DTNB. The compound reacts with the free thiol of CoA, which is released during the citrate synthase 
reaction catalyzed by FrbC, yielding a product at 412 nm. 
 
 Activity of the enzymes FrbD and FrbC was first monitored by Dr. Benjamin Griffin 
from Professor William Metcalf’s laboratory at the University of Illinois. FrbC catalyzes the 
condensation of acetyl CoA with PnPy to form 2-phosphonomethylmalate (2PnMM), an analog 
of citrate
22
. Enzymatic activity was measured by the inclusion of 5,5’-dithiobis(2-nitrobenzoic 
acid) (DTNB) to in vitro reaction mixtures, which reacts with the free thiol of CoA yielding a 
product at 412 nm
31
. These data were able to be reproduced here, feeding the substrate PEP to 
purified FrbD and FrbC in a set of reactions. Only when both enzymes were present in the 
reaction mixture was the product at 412 nm monitored (Figure 2.3). These results show that after 
the PEP mutase reaction catalyzed by FrbD, the FR-900098 pathway undergoes a novel route of 
phosphonate biosynthesis through the citrate synthase homolog FrbC (Figure 2.4). 
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Figure 2.4 PEP mutase activity of FrbD and citrate synthase activity of FrbC. PEP, phosphoenolpyruvate; 
PnPy, phosphonopyruvate; 2PnMM, 2-phosphonomethylmalate; AcCoA; acetyl coenzyme A; CoA, 
coenzyme A. 
 
2.2.2 Reconstitution of Aconitase Activity of FrbA 
 
 Based on homology to the TCA cycle, the next step in FR-900098 biosynthesis was 
proposed to be the aconitase reaction catalyzed by FrbA. This important class of enzymes 
contains an oxygen-sensitive iron-sulfur (Fe-S) cluster that must be assembled and maintained. 
Aconitases contain three conserved cysteine residues which interact with the active [Fe4S4] 
cluster. The three residues function as ligands and coordinate with iron ions, while the fourth 
(labile) iron coordinates with either water or substrate. Based on sequence homology, the 
residues Cys-428, Cys-494, and Cys-497 are responsible for coordination of the cluster. The 
active site of FrbA was modeled after mitochondrial aconitase from pig heart (PDB structure 
7ACN)
32
, which depicts the interaction of the three cysteine residues with the cube-structured 
active [Fe4S4] cluster (Figure 2.5A). 
 Since both elemental iron and sulfur are highly reactive and toxic in vivo, assembly and 
maintenance of Fe-S clusters must be tightly controlled. Three distinct systems which 
accomplish this have been identified to date, termed NIF (nitrogen fixation), ISC (iron-sulfur 
cluster), and SUF (sulfur mobilization)
33
. While the assembly of Fe-S clusters in vivo under 
normal conditions is able to be regulated
34-35
, the cell is unprepared for the burden caused by the 
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overexpression of a recombinant protein like FrbA. The resulting inactive protein can either be 
apoprotein or only contain a [Fe3S4] cluster; although, it is worth noting that some of the cluster 
inactivation may be caused by the purification methods. In order to regain activity of this family 
of enzymes, the active [Fe4S4] cluster must be reconstituted by utilizing parts of the characterized 
assembly operons described above
36
. 
  
 
Figure 2.5 (A) Model of [Fe4S4] cluster in FrbA. Three cysteine residues in the active site of the enzyme 
function as ligands and coordinate with iron ions. The labile (fourth) iron is coordinated with either water 
or substrate in the active form. (B) FrbA following purification by immobilized metal affinity 
chromatography (IMAC) via N-terminal His6-tag. (C) Purified His6-FrbA following anaerobic 
reconstitution of active [Fe4S4] cluster. 
 
 One such enzyme that can accomplish the in vitro reconstitution of Fe-S clusters is the 
cysteine desulfurase IscS. This pyridoxal-5’-phosphate (PLP)-dependent enzyme catalyzes the 
conversion of L-cysteine to L-alanine with the concomitant release of a sulfide ion
37
. With the 
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addition of exogenous iron and 1,4-dithiothreitol (DTT) in an anaerobic environment, the active 
[Fe4S4] cluster of FrbA was able to be reconstituted. A drastic color change in solution was 
monitored from pale brown upon initial purification of FrbA by immobilized metal affinity 
chromatography (IMAC) via N-terminal His6-tag (Figure 2.5B) to a dark brown after anaerobic 
reconstitution of the cluster (Figure 2.5C). FrbA catalyzes the stereo-specific isomerization of 
2PnMM to the isocitrate analog 3-phosphonomethylmalate (3PnMM) (Figure 2.6). 
 
 
Figure 2.6 Aconitase activity of FrbA. 2PnMM, 2-phosphonomethylmalate; 3PnMM, 3-
phosphonomethylmalate. 
 
2.2.3 Isocitrate Dehydrogenase Activity of FrbB and FrbE 
 
 Based on homology to the TCA cycle, the next step in FR-900098 biosynthesis should be 
an isocitrate dehydrogenase reaction. Surprisingly, there are two homologs of this enzyme 
present in the gene cluster, FrbB and FrbE, meaning one or both of them may be capable of 
catalyzing this step in the pathway. Dr. Tyler Johannes performed deletion analysis of these 
genes and observed significantly lower FR-900098 production in the absence of frbB or frbE. 
These two knockout strains were later quantified to both be approximately 5-10% of the 
maximum FR-900098 production level. Furthermore, in the absence of both frbB and frbE, no 
FR-900098 production was observed, indicating that at least one of the genes was required for 
FR-900098 biosynthesis
23
. 
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Figure 2.7 Enzymatic activity of the isocitrate dehydrogenase homologs FrbB and FrbE on the substrate 
3-phosphonomethylmalate (3PnMM) and cofactor NAD
+
. The reaction was monitored by formation of 
NADH at 340 nm. 
 
 In order to assess the function and activity of FrbB and FrbE (and ensure the anaerobic 
reconstitution of FrbA was successful), an in vitro reaction of FrbD, FrbC, and FrbA was 
prepared with the substrate PEP and cofactor AcCoA. This crude reaction mixture containing 
predominantly 3PnMM was then incubated with equimolar FrbB or FrbE and either of the 
potential cofactors NAD
+
 or NADP
+
. The in vitro reaction was monitored by formation of 
NAD(P)H at 340 nm. No reaction was observed with NADP
+
 as the cofactor, indicating that 
NAD
+
 is required in the oxidation of 3PnMM. These assays also revealed that FrbE has a 
significantly higher turnover rate of NAD
+
 compared to FrbB, with the activity of the latter only 
slightly above the negative control (Figure 2.7). 
 These two enzymes were further analyzed as part of the in vitro reconstitution of the full 
FR-900098 biosynthetic pathway, which will be discussed further in Section 2.2.9. Despite the 
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minimal activity of FrbB as seen in the in vitro reactions, this enzyme was still required in the 
context of the full FR-900098 biosynthetic pathway as no FR-900098 production was observed 
in its absence. Interestingly, no FR-900098 production was monitored when FrbE was not 
present as well, even though there was clear turnover of NAD
+
 with the substrate 3PnMM. 
 The full isocitrate dehydrogenase reaction consists of an oxidation followed by a 
decarboxylation step, which is performed by a single enzyme in most cases. Based on the results 
of these experiments, the typically coupled steps are likely decoupled and performed by two 
separate enzymes; oxidation by FrbE and decarboxylation by FrbB (Figure 2.8). 
Nondecarboxylating and decarboxylating variants of isocitrate dehydrogenase have been 
reported in the literature, providing more support for the decoupling of the step in the FR-900098 
biosynthetic pathway
38
. 
 
  
Figure 2.8 Proposed decoupled isocitrate dehydrogranse activity of FrbB and FrbE. 3PnMM, 3-
phosphonomethylmalate; 2OPn, 2-oxo-4-phosphonobutyrate; NAD
+
, oxidized nicotinamide adenine 
dinucleotide; NADH, reduced nicotinamide adenine dinucleotide. 
 
2.2.4 Whole Cell Feeding Assays 
 
 Early attempts to demonstrate in vitro activity of the remaining steps in FR-900098 
biosynthesis using purified enzymes and the proposed substrates as indicated in Figure 2.1 failed. 
Despite this, E. coli knockout experiments analyzed by LC-MS and 
31
P NMR suggested that 
these were the actual substrates, since accumulating intermediates in the pathway would co-elute 
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with the expected authentic standards. In order to identify of the true intermediates in the late 
steps of the pathway, a series of whole cell feeding experiments were conducted. Resting cells of 
E. coli were fed 2-amino-4-phosphonobutyrate (2APn), a glutamate analog which is efficiently 
taken up by the cell and also shown to crossfeed into S. lividans deletion mutants (data not 
shown). Culture supernatants were analyzed by Dr. Paul Thomas of Professor Neil Kelleher’s 
laboratory at the University of Illinois for possible phosphonate intermediates using a coupled 
LC-MS approach. Cells expressing FrbH were found to accumulate CMP-5'-3-
aminopropylphosphonate (CMP-5'-3APn) and cells expressing FrbH, FrbF, and FrbG had 
detectable levels of CMP-5'-N-acetyl-3-aminopropylphosphonate (CMP-5'-Ac3APn), CMP-5'-
FR-900098, and FR-900098. Thus, these initial whole cell feeding assays suggested that 
cytidine-5'-monophosphate (CMP) conjugated phosphonate intermediates are present during the 
late steps of FR-900098 biosynthesis. These studies also showed that FrbG is an essential 
component in the late steps of FR-900098 biosynthesis as definitive assignment of the function 
of the enzyme was never made
22
. It is also interesting to note that 2-oxo-4-phosphonobutyrate 
(2OPn) was detected in samples containing a negative control (empty vector), providing 
evidence that a ubiquitous cellular transaminase is able to carry out the transamination of 2OPn 
to form 2APn. These whole cell feeding studies were done in collaboration with Dr. Tyler 
Johannes
23
. 
 
2.2.5 Transaminase Reaction 
 
 As mentioned in the previous section, the whole cell feeding assays demonstrated that a 
ubiquitous cellular transaminase within E. coli was able to catalyze the conversion of 2OPn to 
2APn. Although a specific transaminase was not present in the FR-900098 biosynthetic cluster, 
one was needed in order to reconstitute the full pathway in vitro. Carl Denard cloned an 
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aminoethylphosphonate (AEP) transaminase from a putative SF-2312 biosynthetic cluster, 
originating from Micromonospora sp. SF-2312
39-40
. This class of enzymes removes the amine 
group from an amino acid (typically L-alanine, L-aspartic acid, or L-glutamic acid) yielding an α-
keto acid (pyruvate, oxaloacetate, or α-ketoglutarate, respectively). Due to the inherent 
reversibility of this enzyme, the AEP transaminase was able to convert 2APn back to 2OPn upon 
incubation with all three of the α-keto acids (Figure 2.9). 
 
 
Figure 2.9.Nonspecific aminotransferase reaction in the FR-900098 biosynthetic pathway. Typical amine 
donors include L-alanine, L-aspartic acid, and L-glutamic acid producing the corresponding keto donors 
pyruvate, oxaloacetate, and α-ketoglutarate, respectively. 2OPn, 2-oxo-4-phosphonobutyrate; 2APn, 2-
amino-4- phosphonobutyrate. 
 
 
2.2.6 Bifunctional Activity of FrbH 
 
 A BLAST search of full-length FrbH revealed two distinct domains: a nucleotide 
transferase domain at the N-terminus followed by a PLP-dependent aminotransferase and/or 
decarboxylase domain at the C-terminus. Only the second domain was originally believed to be 
active, but based on the whole cell feeding studies with 2APn described in Section 2.2.4, we 
investigated whether FrbH was bifunctional. 
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Figure 2.10 Analysis of the FrbH reaction product by HPLC. Negative control contains heat-inactivated 
enzyme. Each peak was also identified by MS analysis. FrbH is able to convert CTP and 2APn to 
predominantly CMP-5’-3APn (m/z 443→322), with a small residual peak of CMP-5’-2APn (m/z 
487→322). CTP, cytidine-5’-triphosphate; CMP-5’-2APn, CMP-5’-2-amino-4-phosphonobutyrate; CMP-
5’-3APn, CMP-5’-3-aminopropylphosphonate. This figure was reprinted with permission from Elsevier 
Journals. Copyright © Chemistry and Biology, 17, 57-64 (2010). 
 
 An in vitro reaction mixture containing both 2APn and cytidine-5’-triphosphate (CTP) 
showed nearly complete conversion of CTP to several compounds, including cytidine-5’-
monophosphate (CMP), cytidine-5’-diphosphate (CDP), CMP-5’-2APn and predominantly 
CMP-5’-3APn (Figure 2.10). LC-MS analysis of the products CMP-5’-2APn and CMP-5’-3APn 
revealed the masses of m/z 487 and 443, respectively. Furthermore, fragmentation of these two 
products in negative mode showed the characteristic fragment ion of m/z 322, corresponding to 
the CMP moiety on both of these compounds. These results suggest FrbH condenses 2APn and 
 37 
CTP to form CMP-5’-2APn and then decarboxylates CMP-5’-2APn to yield CMP-5’-3APn 
(Figure 2.11). These in vitro assays were done in collaboration with Dr. Tyler Johannes
23
. 
  
Figure 2.11 Binfunctional (nucleotide transferase and decarboxylase) activity of FrbH. CTP, cytidine-5’-
triphosphate; 2APn, 2-amino-4-phosphonobutyrate; CMP-5’-3APn, CMP-5’-3-aminopropylphosphonate; 
PPi, pyrophosphate. 
 
 Single point mutations were designed to eliminate the activity of each of the individual 
domains of FrbH to verify the proposed order of reaction. PLP-dependent enzymes are known to 
bind to the cofactor with a conserved lysine residue. A sequence alignment with CobD from 
Salmonella typhirium revealed the PLP-binding motif and the lysine at position 466
41
. A K466A 
mutant was constructed which should be unable to bind the PLP and thus perform the 
decarboxylation. A second mutant was designed to disrupt the nucleotide transferase activity of 
FrbH. A sequence alignment with IspD (an enzyme in the nonmevalonate pathway for isoprenoid 
biosynthesis) from E. coli revealed a common lysine residue (K38 in FrbH) that eliminated the 
enzymatic activity
42
. Under the same in vitro reaction conditions as the wild type FrbH, the 
K466A mutant produced only CMP-5’-2APn. Although unable to totally abolish the nucleotide 
transferase activity, the K38A mutant had a mostly unreacted CTP peak with a small peak 
corresponding to CMP-5’-3APn (Figure 2.12). These results are conclusive evidence for FrbH 
catalyzing the CMP attachment to 2APn followed by decarboxylation, yielding CMP-5’-3APn23. 
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Figure 2.12 Analysis of the mutant FrbH reaction products by HPLC. Each peak was also identified by 
MS analysis. (A) FrbH-K38A mutation should remove nucleotide transferase activity. (B) FrbH-K466A 
mutation should remove decarboxylase activity. CMP, cytidine-5’-monophosphate; CTP, cytidine-5’-
triphosphate; CMP-5’-2APn, CMP-5’-2-amino-4-phosphonobutyrate; CMP-5’-3APn, CMP-5’-3-
aminopropylphosphonate. This figure was reprinted with permission from Elsevier Journals. Copyright © 
Chemistry and Biology, 17, 57-64 (2010). 
 
2.2.7 N-Hydroxylase Activity of FrbG and N-Acetyltransferase Activity of FrbF 
 
 To complete the biosynthesis of FR-900098, the amine group of CMP-5’-3APn requires 
both hydroxylation and acetylation (Figure 2.13). The order and identity of the enzymes 
catalyzing these two steps were never definitively assigned in the original pathway
22
. FrbF has 
strong homology to known N-acetyltransferases and it was originally believed that FrbJ may be 
involved in the N-hydroxylation step. However, based on the results of the deletion studies and 
whole cell feeding assays described in Section 2.2.4, FrbG, a FAD and NADPH dependent N-
hydroxylase, was now thought to catalyze the hydroxylation step. The whole cell feeding studies 
also suggest the order of the two steps as acetylation followed by hydroxylation, since CMP-5’-
Ac3APn was seen and not N-hydroxy-3-aminopropylphosphonate (CMP-5’-H3APn). Coupled in 
vitro reactions with FrbF and FrbG also supported this order of reaction as there was always a 
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CMP-5’-Ac3APn peak present, but little to no CMP-5’-H3APn monitored. To determine the 
order of the acetylation and hydroxylation steps, each of the potential substrates was purified and 
kinetic parameters for FrbF and FrbG were obtained
23
.  
 
 
 
Figure 2.13 Order of the N-hydroxylase and N-acetyltransferase reactions catalyzed by FrbG and FrbF, 
respectively, was originally unknown. CMP-3’-3APn, CMP-5’-3-aminopropylphosphonate; CMP-5’-
H3APn, CMP-5’-N-hydroxy-3-aminopropylphosphonate; CMP-5’-Ac3APn, CMP-5’-N-acetyl-3-
aminopropylphosphonate. 
 
 Although CMP-5’-Ac3APn was believed to be an intermediate in the pathway instead of 
CMP-5’-H3APn, no activity was observed for FrbG towards this substrate. FrbF was able to 
accept either of the two potential substrates, meaning CMP-5’-Ac3APn is actually a dead end in 
the FR-900098 biosynthetic pathway rather than a true intermediate (Table 2.1). Kinetic analysis 
of these two enzymes indicate that FrbF and FrbG compete for the same intermediate, CMP-5’-
3APn, as they both prefer this compound compared to the alternative (CMP-H3APn for FrbF and 
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CMP-5’-Ac3APn for FrbG). However, FrbG has 2.3-fold lower KM for CMP-5’-3APn in 
comparison to FrbF, so the enzyme can effectively direct the flux away from the dead end. The 
most likely reason for observing CMP-5’-Ac3APn rather than CMP-5’-H3APn throughout the 
feeding experiments was differences in soluble expression in E. coli for these two enzymes. 
These results conclusively demonstrate that the flux of the pathway must go through N-
hydroxylation by FrbG followed by N-acetylation by FrbF and subsequently the more 
electrophilic CMP-5’-H3APn intermediate23. 
 
Table 2.1 Kinetic parameters of FrbF and FrbG with each of the potential substrates. NR: no reaction 
detected; SD: standard deviation. This table was reprinted with permission from Elsevier Journals. 
Copyright © Chemistry and Biology, 17, 57-64 (2010). 
 
Enzyme Substrate 
kcat (min
-1
) 
(mean ± SD) 
KM (μM)  
(mean ± SD) 
kcat / KM 
(mM
-1 
min
-1
) 
FrbF CMP-5’-3APn 3.46 ± 0.16 35.2 ± 3.2 98.0 
 CMP-5’-H3APn 2.04 ± 0.43 52.3 ± 3.0 39.0 
FrbG CMP-5’-3APn 5.92 ± 0.38 15.1 ± 1.5 391 
 CMP-5’-Ac3APn   NR 
 
 
2.2.8 Nucleotide Hydrolase Activity of FrbI 
 
 The last step in the biosynthesis of FR-900098 was evident based on the presence of the 
intermediate CMP-5'-FR-900098. Removal of the CMP moiety from CMP-5'-FR-900098 is 
necessary in order to produce the final compound FR-900098. Nucleotide hydrolases are known 
to catalyze the hydrolytic breakdown of a wide variety of nucleotide derivatives
43
. FrbI has high 
homology to this family of enzymes and could likely catalyze the hydrolysis of CMP-5'-FR-
900098 to produce FR-900098 and CMP. In order to perform in vitro enzymatic studies, the 
enzyme FrbI was overexpressed in E. coli and purified to homogeneity. An in vitro reaction 
containing all the components of the FrbH+FrbF+FrbG reaction in addition to FrbI was tested 
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and found to produce a significant amount of FR-900098, whereas only a very small amount of 
FR-900098 was present in the absence of FrbI, likely due to the instability of CMP-5'-FR-
900098 (Figure 2.14). Thus, it is clear that FrbI catalyzes the hydrolysis of CMP-5'-FR-900098 
to form FR-900098 and CMP (Figure 2.15). These in vitro assays were done in collaboration 
with Dr. Tyler Johannes
23
.    
 
 
 
Figure 2.14 Analysis of the FrbI reaction product by LC-MS. Extracted ion chromatograms (m/z 
198→138) of the two reactions show that FrbI is able to convert CMP-5’-FR900098 to FR-900098. This 
figure was reprinted with permission from Elsevier Journals. Copyright © Chemistry and Biology, 17, 57-
64 (2010). 
 
 Interestingly, FrbI also catalyzed the hydrolysis of all the other CMP-containing 
intermediates within the pathway and even showed a small amount of activity toward CTP. This 
is not surprising given that nucleotide hydrolases typically have broad substrate specificity
44
. 
This promiscuous behavior was evident from the gene deletion analysis previously mentioned. 
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The gene frbI is not required for FR-900098 biosynthesis since a ubiquitous nucleotide hydrolase 
is able to cleave the CMP yielding the final compound FR-900098
23
. 
 
 
 
Figure 2.15 Nucleotide hydrolase activity of FrbI. 
 
2.2.9 Full Pathway in vitro Reconstitution 
 
 With all the steps of FR-900098 biosynthesis able to be individually elucidated as 
described in the previous sections, full pathway in vitro reconstitution was completed in a one 
pot synthesis. Inclusion of all the required cofactors and cosubstrates allowed for the production 
of the final product starting from PEP. Of note, FrbI was always excluded from the initial 
reaction mixtures which were left overnight in order to get as complete conversion as possible. 
The reaction mixtures were then treated with the nucleotide hydrolase to remove the CMP 
moiety from all intermediates. Although more FR-900098 was observed in the reaction mixtures 
treated with FrbI, there was always some in the untreated samples due to the inherent instability 
of the compound (Figure 2.16). 
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Figure 2.16 Full pathway in vitro reconstitution. Negative control does not contain the PEP mutase FrbD. 
FR-900098 was observed in the sample not treated with the nucleotide hydrolase FrbI due to the inherent 
instability of the compound CMP-5’-FR-900098. 
 
 Also, the FR-900098 biosynthetic pathway contains the oxygen-sensitive enzyme FrbA 
and one that requires oxygen for catalysis, the N-hydroxylase FrbG. Once the active [Fe4S4] 
cluster of FrbA was reconstituted anaerobically, it appeared to be stable with exposure to air. The 
pathway was able to progress despite the labile iron in the cluster. 
 
 
2.3 Discussion 
 
 The steps of FR-900098 biosynthesis were able to be elucidated by a series of in vitro 
reactions containing purified enzymes (Figure 2.17). The first step was consistent with all other 
phosphonate biosyntheses, the PEP mutase (FrbD) catalyzed conversion of PEP to PnPy. 
However, the next several steps are distinct from other known biosynthetic pathways, where they 
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undergo homologous reactions to the TCA cycle. FrbC first catalyzes substrate condensation 
with AcCoA in a citrate synthase reaction. The enzyme FrbA required anaerobic reconstitution 
of the [Fe4S4] cluster and was able to perform an aconitase reaction. In vitro and in vivo 
experiments suggested that FrbB and FrbE catalyze a decoupled isocitrate dehydrogenase 
reaction, where FrbE catalyzes substrate oxidation followed by decarboxylation by FrbB. 
 Whole cell feeding assays with 2APn in E. coli revealed that intermediates conjugated to 
the nucleotide CMP are present in late steps of FR-900098 biosynthesis. Based on our 
bioinformatic analysis, FrbH contains two functional domains. The enzyme first condenses CTP 
with 2APn to form CMP-5’-2APn followed by decarboxylation of the intermediate to form 
CMP-5’-3APn. In order to obtain the nucleotide conjugated form of FR-900098, the amine group 
of CMP-5’-3APn requires both N-acetylation and N-hydroxylation by FrbF and FrbG, 
respectively. Kinetic analysis of each enzyme with each of the potential substrates reveals that 
flux of the pathway must go through FrbG followed by FrbF and subsequently the more 
electrophilic CMP-5’-H3APn intermediate. Finally, the nucleotide hydrolase FrbI possesses 
broad specificity and can catalyze the hydrolysis of all conjugated intermediates including CMP-
5’-FR-900098, yielding the final product FR-900098. These efforts have expanded our 
knowledge of phosphonate biosynthesis and can now act as a platform for further engineering to 
create novel derivatives of FR-900098 and increase the production of this useful antimalarial. 
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Figure 2.17 Revised biosynthetic pathway for FR-900098 production. Intermediates are as follows: I, 
phosphoenolpyruvate; II, phosphonopyruvate; III, 2-phosphonomethylmalate; IV, 3-
phosphonomethylmalate; V, 3-phosphonomethyloxaloacetate; VI, 2-oxo-4-phosphonobutryate; VII, 2-
amino-4-phosphonobutyrate; VIII, CMP-5’-3-aminopropylphosphonate; IX, CMP-5’-N-hydroxy-3-
aminopropylphosphonate; X, CMP-5’-FR-900098. 
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 We have demonstrated that the late steps of FR-900098 biosynthesis follow a series of 
novel intermediates. Other natural product biosyntheses contain nucleotide conjugated 
intermediates, but attachment of the nucleotide serves only as an activator for otherwise 
challenging chemistry in each of the cases. In the biosynthesis of phosphinothricin tripeptide 
(PTT), PhpF catalyzes the condensation of CTP with phosphonoformate to form CMP-5’-
phosphonoformate (CMP-5’-PF). This reaction was required so the now activated intermediate 
would be primed for transfer of the phosphonoformate group to the appropriate acceptor 
molecule
45
. As part of the nonmevalonate pathway, IspD has been shown to catalyze the 
formation of 4-diphosphocytidyl-2C-methyl-D-erythritol (CDP-ME) from 2C-methyl-D-
erythritol 4-phosphate (MEP) and CTP, which facilitates the subsequent formation of 2-C-
methyl-D-erythritol 2,4-cyclodiphosphate
46
. The nucleotide attachment to intermediates in FR-
900098 biosynthesis clearly does not activate the bond for subsequent chemical reactions. 
Repeated attempts at in vitro reactions with the substrates without CMP failed, emphasizing the 
need for nucleotide attachment. Conjugation to CMP functions as a recognition mechanism to 
help distinguish among other metabolites within the cell and more importantly, a requirement for 
enzymatic activity. This hypothesis was substantiated by our recent determination of the crystal 
structure of FrbG with the cofactor NADPH
47
. Examination of this structure reveals that there is 
no room for the binding of the substrate in the active site. Thus, we proposed a novel reaction 
mechanism for the N-hydroxylation catalyzed by FrbG, which will be discussed in Chapter 3. 
The remaining enzymes in the pathway likely evolved to accept substrates conjugated to CMP 
rather than those proposed in the original pathway. 
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2.4 Conclusions and Outlook 
 
 While investigating the native producer Streptomyces rubellomurinus, Dr. Benjamin 
Griffin and Dr. Paul Thomas obtained LC-MS data suggesting that FR-900098 may be part of a 
larger dipeptide molecule. The final FR-900098-peptide hybrid could have a structure and mode 
of action similar to several other bioactive phosphonates including dehydrophos, rhizocticin, and 
phosphinothricin tripeptide. The additional amino acids convert the phosphonate into an inactive 
“Trojan horse” that is more efficiently taken up by the target organism. Once inside the cell, the 
active phosphonate warhead is released by a nonspecific peptidase
48-50
. The evidence of a 
potential FR-900098-peptide hybrid was further substantiated by the recent annotation of 
portions of the Streptomyces roseosporus NRRL 15998 genome by members of the Broad 
Institute of MIT and Harvard. A nearly identical FR-900098 cluster to the one from S. 
rubellomurinus was present; each gene possessed greater than 65% homology to its counterpart. 
Several genes of interest were adjacent to the homologous FR-900098 biosynthetic cluster 
including NRPS, PKS, and phosphonate-specific transporters (Figure 2.18). These additional 
genes could be responsible for the synthesis of the FR-900098-peptide hybrid. 
 
  
 
 
Figure 2.18 Additional NRPS, PKS, and phosphonate-specific transporter genes adjacent to homologous 
FR-900098 cluster in Streptomyces roseosporus NRRL 15998.  
 
 48 
 DNA assembler, a tool developed by the Zhao laboratory for the rapid construction of 
large recombinant DNA fragments, was utilized to clone the homologous FR-900098 
biosynthetic cluster including the additional NRPS, PKS, and transporter genes
51
. The final 
constructed plasmid also contained sequences for int, an integrase gene, and ΦC31 attP, a 
junction site for integration into S. lividans chromosome. The “complete” FR-900098 
biosynthetic cluster was conjugated into the heterologous host S. lividans, and exconjugants were 
tested for FR-900098 production as a positive control. No production of the compound was 
observed in any of the exconjugants or the original S. roseosporus NRRL 15998. Despite being 
nearly identical to one another, the two clusters are regulated differently to one another. Efforts 
to identify the FR-900098-peptide hybrid must revert to examining S. rubellomurinus and 
potentially S. lividans 4G7. 
 
 
2.5 Materials and Methods 
 
2.5.1 Materials 
 
 Escherichia coli BL21(DE3) and vector pET28a were purchased from Novagen 
(Madison, WI). Overexpression strain for IscS was kindly provided by Professor James Imlay at 
the University of Illinois (Urbana, IL). The compounds L-cysteine (30089), L-alanine (A7469), 
dimethyl-p-phenyldiamine (DPD) (193992), 5,5’-dithiobis(2-nitrobenzoic acid) (DTNB) 
(D8130), ferrous sulfate (Fe(II)SO4) (F7002), phosphoenolpyruvate (PEP) (P7127), acetyl 
coenzyme A (AcCoA) (A2181), (±)-2-amino-4-phosphonobutyric acid (2APn) (A1910), cytidine 
5'-triphosphate (CTP) (C1506), and pyridoxal-5’-phosphate (PLP) (P9255) were purchased from 
Sigma-Aldrich (St. Louis, MO). NADPH was purchased from Jülich Chiral Solutions GmbH 
(Jülich, Germany). 1,4-dithiothreitol (DTT) and NAD
+
 were purchased from Roche Applied 
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Science (Indianapolis, IN). Oligonucleotide primers were obtained from Integrated DNA 
Technologies (Coralville, IA). Phusion
®
 High-Fidelity DNA polymerase, antarctic phosphatase, 
T4 DNA ligase, all restriction enzymes, and protein size markers were purchased from New 
England Biolabs (NEB) (Beverly, MA). PCRs were performed with FailSafe
™
 PCR PreMix 
buffer G from Epicentre Biotechnologies (Madison, WI). The QIAprep spin plasmid miniprep kit 
and QIAquick gel extraction kit were purchased from Qiagen (Valencia, CA). TALON
®
 
Superflow Co
2+
 immobilized metal affinity resin was purchased from Clontech Laboratories 
(Mountain View, CA). SDS-PAGE gel materials, electrophoresis equipment, and size exclusion 
standards were purchased from Bio-Rad (Hercules, CA). All other reagents and materials were 
purchased from either Sigma-Aldrich or Fisher Scientific (Pittsburgh, PA). 
 
2.5.2 Cloning, Expression, and Purification of Proteins 
 
 The original cloning of the FR-900098 biosynthetic genes from fosmid 4G7 was similar 
to that of Eliot et al. and was performed by Dr. Tyler Johannes
22
. Briefly, the gene was PCR 
amplified using primers containing NdeI and HindIII restriction sites and cloned into the 
corresponding sites of pET28a, creating an N-terminal His6-tag. E. coli BL21(DE3) cells 
overexpressing each of the genes were grown in Luria-Bertani (LB) medium supplemented with 
kanamycin (50 µg mL
-1
). Cells were grown at 37°C to OD600~0.7 and then induced at 22°C by 
the addition of IPTG to a final concentration of 0.3 mM. During the purification of FrbH, AEP 
transaminase, and IscS, PLP was added to the media for a final concentration of 50 μg mL-1. The 
culture was incubated at 22°C for an additional 18 hours, after which the cells were harvested by 
centrifugation (10 minutes at 10,000 x g) and resuspended in 20 mM Tris-HCl (pH 7.65), 15% 
glycerol, and 0.5 M NaCl (buffer A).  Lysozyme (1 mg mL
-1
) was added to the resuspended cells 
and the sample was freeze-thawed. The cells were further lysed by sonication (Fisher Scientific 
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Model 500 Ultrasonic Dismembrator) with the amplitude set at 40% and with a pulse sequence 
of 5 seconds on and 10 seconds off, for 5 minutes. The cell debris was removed by centrifugation 
(15 minutes at 15,000 x g). The N-His6-tagged-proteins were purified using immobilized metal 
affinity chromatography (IMAC) coupled with fast performance liquid chromatography (FPLC). 
TALON
™
 Superflow Co
2+
 resin was charged and equilibrated according to the manufacturer’s 
instructions. The clarified supernatant was loaded onto the resin and washed with buffer A. 
Contaminating E. coli proteins were washed off the column with buffer A plus 10 mM 
imidazole. Protein was eluted from the column with buffer A plus 0.2 M imidazole. Elution 
fractions were monitored at wavelength of 280 nm. Protein was concentrated using a Millipore 
Amicon Ultra-15 Centrifugal Filter Device (MWCD 10 kDa) at 4,000 rpm at 4°C, washed three 
times with 50 mM HEPES-Na
+
 buffer (pH 7.25), and concentrated again. SDS-PAGE gel 
electrophoresis was used to assess the presence and purity of protein in the sample. Concentrated 
protein was stored at -80°C in 20% glycerol. 
 
2.5.3 FrbD and FrbC in vitro Assays 
 
 Experiments used to assay the activity of FrbD and FrbC were performed similar to that 
to that of Eliot et al. with some modifications
22
. Each reaction mixture (100 µL final volume) 
contained 1 mM PEP, 10 mM MgCl2, 1 mM AcCoA, and 2 mM DTNB in 50 mM HEPES-Na
+
 
buffer (pH 7.25). Reactions were initiated by the addition of 5 µM FrbD, 5 µM FrbC, or a 
combination of both enzymes and run at 30°C. Enzymatic activity was monitored by the increase 
in absorbance at 412 nm using a Varian Cary 100 Bio UV-visible spectrophotometer (Varian, 
Palo Alto, CA). 
 
 
 51 
2.5.4 Reconstitution of FrbA 
 
 Overexpression strain for IscS was obtained from Dr. Soojin Jang in Professor James 
Imlay’s laboratory. The construct contained a His6-tag making it amenable to purification by 
IMAC coupled to FPLC as described in Section 2.5.2. Activity of the cysteine desulfurase was 
first verified through a two step reaction carried out in an anerobic chamber. Each reaction 
mixture (800 µL final volume) contained 25 mM L-cysteine, 50 mM 1,4-dithiothreitol (DTT), 
and increasing volumes of purified IscS (0-40 μL) in 50 mM Tris-HCl buffer (pH 7.65). 
Reactions were incubated at 37°C for 5 minutes before quenching with 20% trichloroacetic acid 
(TCA). Precipitated protein was removed by centrifugation (5 minutes at 15,000 x g). A second 
set of reaction mixtures (1 mL final volume) contained 500 µL supernatant from previous step, 2 
mM dimethyl-p-phenyldiamine (DPD), and 3 mM Fe(III)Cl3 in 50 mM Tris-HCl buffer (pH 
7.65). Reactions were incubated at room temperature for 30 minutes in the dark. Enzymatic 
activity was monitored by the formation of methylene blue (from two equivalents of DPD and a 
sulfide ion) by the increase in absorbance at 670 nm using a Varian Cary 100 Bio UV-visible 
spectrophotometer (Varian, Palo Alto, CA). 
 Upon confirmation of active IscS, the active [Fe4S4] cluster of FrbA was reconstituted; 
performed again in an anaerobic chamber. Each reaction mixture (100 µL final volume) 
contained 25 mM L-cysteine, 50 mM DTT, 10 mM Fe(II)SO4, purified IscS, and purified FrbA. 
The reaction was incubated at room temperature for 1 hour. A distinct color change from a pale 
to dark brown accompanied the reconstitution of the active FrbA cluster. 
 
2.5.5 FrbB and FrbE in vitro Assays 
 
 The assay mixture (300 μL final volume) used to produce the substrate 3-
phosphonomethylmalate (3PnMM) contained 1 mM PEP, 10 mM MgCl2, 1 mM AcCoA, 10 µM 
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FrbD, 10 µM FrbC, and 10 µM reconstituted FrbA in 50 mM HEPES-Na
+
 buffer (pH 7.5).  
Reactions were initiated by the addition of enzymes and incubated at 30°C for 2 hours. Samples 
were then transferred into a Microcon® centrifugal filter device (MWCO 10,000) (Millipore, 
Billerica, MA) and centrifuged for 10 minutes at maximum speed in a microcentrifuge to remove 
all enzymes. 
 Experiments used to assay the activity of FrbB and FrbE (100 μL final volume) contained 
25 μL FrbDCA reaction mixture and 1 mM NAD(P)+ in 50 mM HEPES-Na+ buffer (pH 7.5). 
Reactions were initiated by the addition of either 2 µM FrbB or 2 µM FrbE and run at 30°C. 
Enzymatic activity was monitored by the increase in absorbance at 340 nm using a Varian Cary 
100 Bio UV-visible spectrophotometer (Varian, Palo Alto, CA). 
 
2.5.6 Whole Cell Feeding Assays 
 
 E. coli BL21(DE3) cells expressing empty vector (control), FrbH and FrbHFG-DxrB 
were cultured overnight at 37°C in Terrific Broth (TB) medium with appropriate antibiotics. The 
cultures were diluted 1:100 in fresh medium and grown at 37°C to an OD600~0.7. Protein 
expression was induced by the addition of 0.3 mM IPTG final concentration and cultures were 
grown at 25°C for 24 hours. Cultures were then centrifuged at 4,000 rpm for 15 minutes and the 
supernatant was discarded. The cell pellet was resuspended in 1 mL of 10 mM Tris-HCl buffer 
(pH 7.0). Resuspended cells were mixed with 20 mM final concentration (±)-2-amino-4-
phosphonobutyrate (2APn) and incubated at 30°C for 24 hours. Samples were lysed by 
freeze/thaw and centrifuged at maximum speed in a microcentrifuge for 10 minutes. The 
supernatant (1 mL) was mixed with 9 mL of methanol, vortexed, and centrifuged at 4,000 rpm 
for 15 minutes. The pellet was discarded and the supernatant was rotovaped down to a volume of 
1 mL. Samples were placed in the -80°C freezer until analyzed by LC-MS using a 7 Tesla LTQ-
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FT mass spectrometer (Thermo Finnigan, San Jose, CA). The LC-MS analysis for these 
experiments was conducted by Dr. Paul Thomas of Professor Neil Kelleher’s laboratory at the 
University of Illinois. 
 
2.5.7 FrbH in vitro Assays 
 
The assay mixture (100 μL final volume) contained 1 mM (±)-2-amino-4-
phosphonobutyric acid, 1 mM CTP, 10 mM MgCl2, and 5 μM FrbH in 50 mM HEPES-Na
+
 
buffer (pH 7.5). Reactions were initiated by the addition FrbH to the reaction mixture and 
incubated at 30°C for 2 hours. Samples were then transferred into a Microcon® centrifugal filter 
device (MWCO 10,000) (Millipore, Billerica, MA) and centrifuged for 10 minutes at maximum 
speed in a microcentrifuge. After filtering, reactions were analyzed by LC-MS.  
 
2.5.8 Site-directed Mutagenesis of FrbH 
 
 A megaprimer PCR method was utilized to introduce site-specific mutations into the frbH 
gene using pET28a-frbH plasmid as the template
52
. The original cloning primers frbH-for-NdeI 
and frbH-rev-HindIII were used in combination with one of the mutagenic primers listed in 
Table 2.2. The frbH-K38A megaprimer was first amplified using the mutagenic (forward) primer 
and reverse cloning primer, while the frbH-K466A megaprimer first amplified using the 
mutagenic (reverse) primer and forward cloning primer. The megaprimers were then extracted 
and purified from the agarose gel after DNA electrophoresis. A second PCR amplified the full-
length genes using the opposite cloning primer as the previous PCR (forward for frbH-K38A and 
reverse for frbH-K466A) and the corresponding megaprimer from the previous reaction. The 
correctly sized genes were gel extracted and then digested with NdeI and HindIII. The digested 
mutant gene was ligated into dephosphorylated plasmid pET28a which was digested with the 
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same two restriction enzymes. Chemically competent E. coli BL21(DE3) were transformed with 
the ligation mixtures by heat shock treatment and grown on LB plates supplemented with 
kanamycin (50 µg mL
-1
). Several colonies were picked and clones were checked by digestion 
analysis to ensure the correctly sized gene was present. Purified plasmids were submitted to 
ACGT, Inc. (Wheeling, IL) for sequencing to confirm the desired mutation as well as eliminate 
the chance of introducing random mutations during either of the PCR steps. Final constructs 
contained His6-tags making them amenable to purification by IMAC coupled to FPLC as 
described in Section 2.5.2. 
 
Table 2.2 Primer sequences used in site-directed mutagenesis of frbH. Mutated codons are italicized. 
 
Site Sequence 
Megaprimer 
Length (bp) 
K38A CCGGCGGCCC GCG CCGCTCACCCCG 1789 
K466A GACGCCGTAGAC GGC GCTGATGCTCTT 1410 
 
 
 
2.5.9 Kinetic Analysis of FrbF and FrbG 
 
 Kinetic assays were performed using a Varian Cary 100 Bio UV-visible 
spectrophotometer (Varian, Palo Alto, CA) in triplicate at 30°C. A 100 μL reaction mixture 
containing 0.5 μM FrbF, 2 mM 5,5’-dithiobis(2-nitrobenzoic acid) (DTNB), and substrate 
(concentrations varied from 0-2 mM) in 50 mM HEPES buffer (pH 7.5) was incubated for 5 
minutes. The reaction was initiated by addition of 500 μM AcCoA and then monitored by the 
increase in absorbance at 412 nm (ε412 = 13.6 mM
-1
cm
-1
). A 100 μL reaction mixture containing 
1 μM FrbG and substrate (concentrations varied from 0-2 mM) in 50 mM HEPES buffer (pH 
7.5) was incubated for 5 minutes. The reaction was initiated by addition of 200 μM NADPH and 
then monitored by the decrease in absorbance at 340 nm (ε340 = 6.22 mM
-1
cm
-1
). 
 
 55 
2.5.10 FrbI in vitro Assays 
 
The assay mixture (100 μL final volume) contained 1 mM (±)-2-amino-4-
phosphonobutyric acid, 1 mM CTP, 10 mM MgCl2, 1 mM AcCoA, 1 mM NADPH, 5 μM FrbH, 
5 μM FrbF, 5 μM FrbG, and 5 μM FrbI in 50 mM HEPES-Na+ buffer (pH 7.5).  Reactions were 
initiated by the addition of FrbI to the reaction mixture and incubated at 30°C for 2 hours.  
Samples were then transferred into a Microcon® centrifugal filter device (MWCO 10,000) and 
centrifuged for 10 minutes at maximum speed in a microcentrifuge. After filtering, reactions 
were analyzed by LC-MS.  
 
2.5.11 Full FR-900098 Biosynthetic Pathway Reconstitution 
 
 The assay mixture (400 μL final volume) contained 1 mM PEP, 10 mM MgCl2, 2 mM 
AcCoA, 1 mM NAD
+
, 1 mM CTP, 1 mM NADPH, 1 mM PLP, 1 mM L-alanine, 5 μM FrbD, 5 
μM FrbC, 5 μM reconstituted FrbA, 5 μM FrbB, 5 μM FrbE, 5 μM AEP transaminase, 5 μM 
FrbH, 5 μM FrbF, and 5 μM FrbG in 50 mM HEPES-Na+ buffer (pH 7.5).  Reactions were 
initiated by the addition of enzymes to the reaction mixture and incubated at room temperature 
overnight. The reactions were then treated with 5 μM FrbI for nucleotide removal. Samples were 
then transferred into a Microcon® centrifugal filter device (MWCO 10,000) and centrifuged for 
10 minutes at maximum speed in a microcentrifuge. After filtering, reactions were analyzed by 
LC-MS. 
 
2.5.12 LC-MS Analysis 
 
 Products of the enzymatic reactions were analyzed by an Agilent 1100 series LC/MSD 
XCT plus ion trap mass spectrometer (Agilent, Palo Alto, CA) at the Roy J. Carver 
Metabolomics Center at the University of Illinois (Urbana, IL).  The liquid chromatography (LC) 
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was performed using an Agilent 1100 series HPLC equipped with an online degasser, binary 
pump, and autosampler.  The mass spectrometry (MS) was performed using an Agilent XCT ion 
trap MSD mass spectrometer.  The MS system was operated using a drying temperature of 
350°C, a nebulizer pressure of 35 psi, a drying gas flow of 8.5 L min
-1
, and a capillary voltage of 
4500 V.  For the CMP-containing compounds, analytes were resolved on a 150 × 4.6 mm C18 
reverse-phase HPLC column (Agilent, Palo Alto, CA).  HPLC parameters were as follows: 
solvent A: 15 mM ammonium formate; solvent B: 20 mM ammonium acetate; 25% solvent B at 
0 minutes; gradient 100% solvent B in 10 minutes, and 100% solvent B for 3 minutes; flow rate: 
0.3 mL min
-1
; detection by UV absorbance at 254 nm.  Mass spectra were acquired in ultra scan 
mode using electrospray ionization (ESI) with negative polarity.  For the non-CMP-containing 
compounds, analytes were resolved on a 100 x 4.6 mm Synergi 4u Fusion-RP 80A analytical 
column (Phenomenex, Torrance, CA).  HPLC parameters were as follows: solvent A: 0.1% 
formic acid in ddH2O; solvent B: 100% acetonitrile; gradient of 0 to 40% solvent B for 10 
minutes, a gradient of 40 to 100% solvent B for 3 minutes, and 100% solvent B for 5 minutes; 
flow rate of 200 µL min
-1
.  Mass spectra were acquired in ultra scan mode using electrospray 
ionization with positive polarity. 
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Chapter 3: Characterization of the NADPH and FAD Dependent 
N-Hydroxylase FrbG 
 
 
3.1 Introduction 
 
 Initial sequence comparison of FrbG using the bioinformatics tool BLAST failed to 
identify any known enzymes of strong sequence similarity. Only weak sequence homology to the 
small subunit of glutamate synthase was identified. As a result, no role in the biosynthetic 
pathway was originally proposed for the enzyme
1
. Further characterization of the pathway as 
detailed in Chapter 2 established that FrbG was indeed required in the biosynthesis of FR-
900098. Deletion analysis demonstrated that the enzyme was an essential component for 
heterologous production of FR-900098 in E. coli.  Moreover, feeding studies with the 
intermediate 2-amino-4-phosphonobutyrate (2APn) indicated that the enzyme catalyzed a 
reaction in the late steps of FR-900098 biosynthesis. In vitro reaction mixtures with purified 
enzyme later confirmed that FrbG catalyzed the N-hydroxylation to install the hydroxamate 
moiety in the final product
2
. 
 Flavoproteins are highly efficient enzyme systems responsible for the addition of 
molecular oxygen to a wide variety of substrates including organic compounds, drugs, and 
xenobiotics
3
. Flavin-containing monooxygenases (FMOs) and the closely related microbial N-
hydroxylating monooxygenases (NMOs) represent a subclass of these enzymes that perform the 
oxygenation of compounds containing soft nucleophiles such as nitrogen and sulfur
4-5
 or the 
hydroxylation of nitrogens producing hydroxylamines
6
. N-hydroxylation of primary amines, 
similar to the FrbG reaction, are known to occur in the biosynthetic pathways of valanimycin 
from Streptomyces viridifaciens
7
 and pyoverdin from Pseudomonas aeruginosa
8
. FrbG possesses 
the classic Rossman fold dinucleotide-binding motif (DBM) with the GXGXXG and modified 
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GGAHSA motifs that bind the adenosine-5’-disphosphate (ADP) moiety of FAD and NADPH, 
respectively
9
. However, the enzyme does lack the motifs common to FMOs such as the FATGY 
motif that is retained in N-hydroxylating siderphore enzymes from bacteria and fungi and the 
FXGXXXHXXXY fingerprint that occurs just before the NAD(P)H binding GXGXX(G/A) 
motif
4
. The presence and absence of the common FMO and NMO motifs may indicate some 
novel structural and catalytic elements of FrbG compared to other characterized enzymes within 
this subclass. 
 
 
 
Figure 3.1 Catalytic cycle for a typical FAD and NADPH dependent FMO system. Flavin reduction and 
formation of C4α-hydroperoxyflavin intermediate occurs upon binding of NADPH and molecular 
oxygen. The oxidized NADP
+
 stabilizes formation of the reactive intermediate until binding of the 
substrate. In the absence of substrate, there is solvent mediated decay to hydrogen peroxide (H2O2) and 
the oxidized flavin over time. 
 
 FMOs and NMOs consist of a single polypeptide that can catalyze both 
monooxygenation and flavin reduction using NADPH cofactor as an electron donor to reduce a 
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prosthetic FAD group. This unusual catalytic mechanism sets it apart from other monooxygenase 
systems such as cytochrome P450s
3
. FMOs and NMOs do not require the presence of the 
substrate for the reduction of FAD by NADPH
10
. Instead, the bound cofactor reacts with 
molecular oxygen to form a very reactive, yet fairly unstable C4α-hydroperoxyflavin 
intermediate, which is now primed to function as either an oxygenase (FMO) or N-hydroxylase 
(NMO)
3
. Conformational changes within the enzyme move the now oxidized NADP
+
 away from 
the reduced FADH2 into a “post-hydride transfer” conformation, where it is now poised to 
stabilize the intermediate and await binding of the substrate (Figure 3.1). Thus far, only the 
“post-hydride transfer” state has been observed in crystal structures of FMOs and NMOs11-13. 
This chapter will focus on the expression, purification, and biochemical characterization of FrbG 
in combination with structural analysis from Professor Satish Nair’s laboratory at the University 
of Illinois to gain insights into the catalytic mechanism of this enzyme. 
 
 
3.2 Results 
 
3.2.1 Biochemical Analysis 
 
 The full-length frbG gene (1314 bp) was cloned from fosmid 4G7 into pET28a, creating 
an N-terminal His6-tag. E. coli BL21(DE3) cells were transformed with this construct and lysates 
of IPTG-induced cultures were analyzed by SDS-PAGE to check for the presence of soluble 
protein
14
. A clear overexpression band for FrbG was detected, which constituted approximately 
50% of the total soluble cellular protein (Figure 3.2). The His6-tag allowed for the single step 
purification of the enzyme using immobilized metal affinity chromatography (IMAC) with 
TALON Superflow Co
2+
 resin coupled with fast performance liquid chromatography (FPLC). 
The purity of FrbG (47.9 kDa) was also analyzed by SDS-PAGE (Figure 3.2) and was greater 
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than 95%. The concentration of final enzyme stocks was determined by the Bradford method
15
 
and an estimated extinction coefficient of 51.5 mM
-1
 cm
-1
 at 280 nm (San Diego Supercomputer 
Center Biology WorkBench [http://workbench.sdsc.edu])
16
, each providing similar results.  
 
 
 
Figure 3.2 Overexpression and purification of recombinant FrbG in E. coli BL21(DE3). Lane M, protein 
standard (kDa); lane 1, cell-free lysate of empty pET28a; lane 2, cell-free lysate of induced FrbG culture; 
lane 3, purified FrbG enzyme. 
 
 Upon purification, in the absence of exogenous compounds added to the media or buffer, 
the FrbG solution appeared bright yellow. Cellular FAD became bound to the enzyme, which 
remained attached throughout the purification process. This family of enzymes also requires 
NADPH which functions as an electron donor to the prosthetic FAD group. In vitro reaction 
mixtures lacking NADPH were unable to catalyze substrate N-hydroxylation demonstrating that, 
unlike FAD, this cofactor was not pulled down during FrbG purification and its addition was 
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required. FrbG demonstrated high specificity for this cofactor as the enzyme had very low 
activity when supplied NADH as the electron donor for the reaction
17
. 
 
  
 
Figure 3.3 Analysis of the FrbG reaction product by HPLC. Negative control contains heat-inactivated 
enzyme. Each peak was also identified by MS analysis. FrbG is able to convert CMP-5’-3APn (m/z 
443→322) to CMP-5’-H3APn (m/z 459→322). The enzyme was inactive on the substrate lacking 
nucleotide conjugation (inset). CMP-5’-3APn, CMP-5’-3-aminopropylphosphonate; CMP-5’-H3APn, 
CMP-5’-N-hydroxy-3-aminopropylphosphonate; 3APn, 3-aminopropylphosphonate. 
 
 
 After incubating purified FrbG with the substrate CMP-5’-3-aminopropylphopshonate 
(CMP-5’-3APn) and NADPH, we were able to monitor conversion to CMP-5’-N-hydroxy-3-
aminopropylphopshonate (CMP-5’-H3APn) by HPLC (Figure 3.3). Product formation was 
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further confirmed by LC-MS, where the new peak displayed the expected fragmentation (m/z 
459→322) of the hydroxylamine (Figure 3.4). 
 
 
 
Figure 3.4 N-hydroxylase activity of FrbG. 
 
 
3.2.2 Summary of Structural Analysis 
 
 Crystals of full-length FrbG (437 amino acids) were obtained by Kim Nguyen of 
Professor Satish Nair’s laboratory at the University of Illinois, and the crystal structure with 
bound NADPH
 
and FAD was determined to a resolution of 1.6 Å (Figure 3.5). FrbG is composed 
of two structural domains. Residues 167 – 340 form a small (NADPH binding) domain and 
residues 1 – 166 along with 341 – 430 form the larger (FAD binding) domain. The two domains 
are situated close to one another such that a single channel extends between them at the core of 
FrbG. The cofactors NADPH and FAD are located at the interface of the small and large 
domains, which is the site for enzyme catalysis. Although the overall fold of FrbG is similar to 
those of other FMOs, there are several distinct insertions and structural rearrangements of 
secondary elements
17
. 
 The prosthetic group FAD is situated exclusively in the region of the channel formed by 
the larger domain. Although the isoalloxazine ring extends towards the interaction domain of 
FrbG to react with the nicotinamide ring of NADPH, FAD remains predominantly embedded and 
surrounded by a network of water molecules. Additional examination of the crystal structure 
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indicated that NADPH is more loosely bound in the enzyme compared to FAD, since both its 
adenine nucleotide and pyrophosphates are exposed to solvent. Interestingly, there is no room for 
the CMP-5’-3APn substrate in this channel, providing evidence that the substrate and NADPH 
cofactor might bind alternatively. Attempts to soak FrbG crystals with NADP
+
 resulted in 
immediate cracking, indicating that the enzyme likely undergoes a structural rearrangement 
following FAD reduction by NADPH. Our crystal structure of FrbG also represents the first 
structure of a “pre-hydride transfer” conformation of a flavin monooxygenase. The cofactors are 
situated in FrbG with distance and orientation compatible with NADPH prepared to reduce the 
isoalloxazine ring of FAD
17
. 
 The position of Asn-58 near the isoalloxazine ring of FAD in FrbG is indicative of 
having the same function as Asn-91 of the FMO from Schizosaccharomyces pombe
11
. This 
residue engages in hydrogen bonding interactions with a water molecule near the C4α position of 
the flavin and is also in close proximity to dioxygen in the S. pombe structure. The positioning 
and hydrogen bonding interactions of Asn-58 in FrbG suggest that this residue serves the 
essential function of providing molecular oxygen to the reduced flavin group for the formation of 
the C4α-hydroperoxyflavin intermediate17. The lack of a substrate binding pocket within the 
active site in the FrbG-FAD-NADPH complex indicates that substrate and cofactor occupy 
overlapping binding sites, consistent with observations in the S. pombe FMO, where the substrate 
methimazole occupies the same binding site as NADP
+
. Also, dioxygen acceptance may only 
occur in the presence of substrate as it did with FMO from S. pombe
11
. Our crystallographic 
studies did not show molecular oxygen bound to the flavin ring. The Asn-58 was one of several 
key residues that were targeted for mutational analysis in Section 3.2.5. Overall, the structural 
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analysis described in this section revealed important clues into the reaction mechanism for FrbG, 
which will be further analyzed by a series of biochemical assays. 
 
 
 
Figure 3.5 Crystal structure of FrbG obtained by Kim Nguyen of Professor Satish Nair’s laboratory at the 
University of Illinois to a resolution of 1.6 Å. The two structural domains of the enzyme are depicted in 
cyan and purple as well as incorporated FAD and NADPH. FAD, flavin adenine dinucleotide; NADPH, 
reduced nicotinamide adenine dinucleotide phosphate. 
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3.2.3 Determination of Quaternary Structure 
 
 The quaternary structure of FrbG was determined based on the retention times of a Bio-
Rad molecular mass standard. The molecular mass of native, active FrbG was calculated to be 
~48 kDa (Figure 3.6). Since the native protein eluted as a monomer, further monomerization 
using SDS was not pursued. In the crystal structure obtained from Professor Satish Nair’s 
laboratory, one molecule of FrbG binds one molecule of NADPH
 
and FAD and there is one 
protein-FAD-NADPH complex per asymmetric unit. These data combined with our quaternary 
structure analysis confirmed that native FrbG exists as a monomer in solution
17
. 
 
 
 
Figure 3.6 HPLC size exclusion chromatography of FrbG.  A Bio-Rad size exclusion standard was used 
to generate the calibration curve.  The standard proteins are represented by closed squares and FrbG 
sample is represented by an open square.  
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3.2.4 Kinetic Analysis 
 
 Steady state kinetic analysis was performed at a fixed concentration of NADPH with 
substrates selected as they were applicable to the proposed biosynthetic pathway of FR-900098. 
Based on the originally proposed FR-900098 biosynthetic pathway, FrbG was believed to N-
hydroxylate either 3-aminopropylphosphonate (3APn) or N-acetyl-3-aminopropylphosphonate 
(Ac3APn)
1
. However, we have recently demonstrated that the later steps in the pathway contain 
phosphonate intermediates conjugated to cytidine-5’-monophosphate (CMP), so our kinetic 
analysis also included CMP-5’-3APn and CMP-5’-Ac3APn2.   
 The enzymatic activity was first monitored by the consumption of NADPH at a 
wavelength of 340 nm. FrbG only demonstrated activity towards one of the four potential 
substrates, CMP-5’-3APn (Table 3.1).  The enzyme had a low KM of 15.1 μM, but also a 
relatively low kcat of 5.92 min
-1
.  However, many enzymes associated with secondary metabolism 
tend to have lower turnover numbers as a means to prevent drawing cellular resources from 
primary metabolism.  The crystal structure of FrbG suggested that the cofactor NADPH and 
substrate actually compete for the same binding pocket.  As a result, NADPH used at saturated 
concentrations (300 μM) for the steady state kinetic analysis may have caused little to no 
catalysis of the second CMP-conjugated intermediate, CMP-5’-Ac3APn.  The KM of FrbG with 
NADPH was estimated to be 7 μM, yet FrbG still remained inactive on CMP-5’-Ac3APn when 
the NADPH concentration was reduced to 10 μM. The narrow channel inside of the 
NADPH/substrate binding site of FrbG likely contributes to this tight substrate specificity in that 
the substrates must be of the appropriate length and charge to access the C4α-hydroperoxyflavin 
intermediate within the channel for completion of catalysis to occur
17
. 
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Table 3.1 Kinetic parameters of FrbG measured from NADPH oxidation assays. NR: no reaction 
detected; SD: standard deviation. 
 
Substrate 
kcat (min
-1
) 
(mean ± SD) 
KM (μM)  
(mean ± SD) 
kcat / KM 
(mM
-1 
min
-1
) 
CMP-5’-3APn 5.92 ± 0.38 15.1 ± 1.5 391 
CMP-5’-Ac3APn   NR 
3APn   NR 
Ac3APn   NR 
 
 Kinetic analysis of FrbG was also performed by tracking hydroxylated product formation 
by LC-MS. Only CMP-5’-3APn was used as a substrate for these assays since it was determined 
to be the only active substrate of the four. Unlike in the NADPH oxidation assays, inhibition of 
the initial velocity of the enzymatic reaction was monitored at increasing concentrations of the 
substrate (Figure 3.7). The maximum reaction velocity was observed at approximately 150 µM 
CMP-5’-3APn, above which the initial velocity for the hydroxylation assay continued to 
decrease at all concentrations tested up to 750 µM. The data were used to fit the substrate 
inhibition model of enzyme kinetics in GraphPad Prism 5 in order to obtain kinetic parameters of 
FrbG, including the inhibition constant KI (283 ± 73 µM). These data further suggest that the 
CMP-5’-3APn substrate and NADPH cofactor compete for the same binding pocket17. Substrate 
inhibition has been demonstrated for several other enzymes in this family, p-hydroxybenzoate 
hydroxylase (PHBH)
18
 and lysine hydroxylase (IucD)
19
, each possessing a reaction mechanism 
distinct from typical FMOs. Similar to FrbG, inhibition is not monitored in the NADPH 
oxidation assays, indicating an uncoupling between NADPH oxidation and hydroxylated product 
formation
20-21
. Increasing amounts of substrate does not inhibit oxidation of the cofactor, 
ultimately leading to an increase in production of hydrogen peroxide (H2O2)
20
. 
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Figure 3.7 Kinetic analysis of FrbG as determined by hydroxylated product formation. Inhibition of 
initial velocity rates was monitored for increasing concentration of CMP-5’-3APn substrate, indicating 
competition with NADPH cofactor for the same binding pocket. 
 
 
3.2.5 Mutational Analysis 
 
 The crystal structure of FrbG provided a means to identify residues of interest for 
mutational analysis. In addition to the structure with bound FAD and NADPH, a docking model 
of CMP-5’-3APn in the NADPH binding domain was created. Under the hypothesis that 
substrate and cofactor recognition occurs via the nucleotide group, the adenine moiety of 
NADPH was aligned with the cytosine moiety of the substrate in order to create the model. The 
model resulted in the placement of the amine tail of 3APn directly above the isoalloxazine ring, 
adjacent to the C4α where molecular oxygen is proposed to bind and catalysis is to occur (Figure 
3.8). Asn-58 was already mentioned in Section 3.2.2 as a potentially important key residue to the 
catalytic cycle of FrbG. The main chain nitrogen of the residue forms hydrogen bonds with the 
O4 of the isoalloxazine ring, but more importantly, Asn-58 is thought to be crucial in supplying 
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molecular oxygen to FAD and stabilizing the resultant C4α-hydroperoxyflavin intermediate. The 
next residue targeted for mutational analysis was His-221. The main chain nitrogen atom of this 
residue anchors one of the nicotinamide pyrophosphates of NADPH via hydrogen bonding. 
Investigation of a docking model containing CMP-5’-3APn revealed that the orientation of the 
amine tail of the substrate is likely also fixed by His-221. The final residue of interest identified 
in the structure was Arg-250. The side chain nitrogens of this residue hydrogen bonds to the 
phosphate present on the 2’ carbon of the adenosine ribose of NADPH as well as engages in 
stacking interactions with adenine nucleotide of NADPH and subsequently the cytosine ring of 
CMP-5’-3APn. This residue could provide the means of recognition for the cofactor and 
substrate in the NADPH binding pocket of FrbG. Site-specific alanine mutants were created for 
each of three residues identified in the crystal structure and docking model
17
. 
 
 
Figure 3.8 Hypothetical model for the interactions of CMP-5’-3APn substrate in the active site of FrbG. 
Adenine moiety of NADPH cofactor was aligned with the cytosine moiety of substrate in order to create 
this model. CMP-5’-3APn is shown in cyan and isoalloxazine ring of FAD is shown in purple. 
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 The resulting proteins were purified to homogeneity and then assayed for NADPH 
oxidase activity in the absence of substrate and catalytic activity in the presence of substrate 
(Figure 3.9). FrbG-N58A demonstrated the importance of this residue in the catalytic cycle of the 
enzyme. This mutant, while still exhibiting NADPH oxidase activity at a slightly elevated level 
compared to the wild type enzyme, was not active on the CMP-5’-3APn substrate. The mutant 
may not be able to stabilize the C4α-hydroperoxyflavin intermediate long enough for the 
substrate to enter into the binding pocket and complete the hydroxylation. FrbG-H221A had 
significantly higher rates for both NADPH oxidation and substrate hydroxylation compared to 
the wild type FrbG. The alanine substitution at this residue opened up the binding pocket and 
removed the hydrogen bond with the cofactor, thus favoring faster turnover of NADPH. Overall, 
FrbG-R250A had similar rates compared to the wild type enzyme, with only slight decreases in 
both. This residue may help provide some support to the nucleotides of both cofactor and 
substrate, but it is not the sole determinant
17
. 
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Figure 3.9 Mutational analysis of Asn-58, His-221, and Arg-250 in FrbG. Wild type and mutant proteins 
were tested for NADPH oxidase activity (in the absence of substrate) as well as enzymatic activity in the 
presence of CMP-5’-3APn substrate.  
 
 
3.2.6 Isolation of C4α-Hydroperoxyflavin Intermediate 
 
Fully oxidized FrbG displays the expected maxima at 265, 369, and 450 nm with a 
shoulder at 475 nm (Figure 3.10, trace A). Stabilization of the C4α-hydroperoxyflavin 
intermediate has been well documented for several other FMOs
12,22-24
. In these enzymes, mixing 
equimolar protein and NADPH in an aerated buffer solution lead to immediate formation of the 
highly stable intermediate, with a characteristic peak at ~360 nm
22,25-27
. Upon addition of 
NADPH to FrbG, an increase in absorbance and shift to 349 nm was recorded, instead of the 
expected peak (trace B). After 15 minutes, the spectrum resembled the C4α-hydroperoxyflavin 
intermediate with the peak now centered at 360 nm (trace F). In typical FMOs, the flavin will 
 76 
become reduced immediately (seen as a shoulder at 450 nm). Due to the inherent NADPH 
oxidase activity of this family of enzymes, the spectrum will slowly revert to the oxidized flavin 
as hydrogen peroxide (H2O2) is released from the FMO
12
. FrbG displayed a slow decrease in the 
observed peak at 450 nm, instead of immediate formation of the fully reduced flavin (traces B-
D). This peak reached a minimum after approximately 5 minutes, followed by an increase in 
absorbance as the spectrum reacquires the characteristic trace of oxidized flavin (traces E-F). The 
fully reduced flavin was unable to be obtained under several other experimental conditions. 
Addition of 10-fold excess NADPH to both aerobic and anaerobic solutions did not demonstrate 
complete flavin reduction. Inclusion of NADP
+
 to the solution also did not improve the reduction 
of FrbG. In fact, the oxidized cofactor inhibited the speed of flavin reduction compared to 
NADPH alone
17
. 
This occurrence can be explained by the proposed “gatekeeper” role of NADP+ in 
FMOs
28
. The normally tightly bound cofactor helps stabilize the C4α-hydroperoxyflavin 
intermediate, preventing rapid formation of H2O2 in the absence of substrate. These studies 
further suggest alternate binding between the substrate and the cofactor, making the intermediate 
more susceptible to NADPH oxidase activity compared to the case where NADP
+
 is the final 
product to be released
17
. 
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Figure 3.10 Absorbance spectra of FrbG. Trace A represents the fully oxidized form of the enzyme (at a 
concentration of 7 µM) in the absence of NADPH. Trace B was obtained immediately after addition of 
equimolar NADPH under aerobic conditions. Traces C-F were recorded 1 min, 5 min, 10 min, and 15 min 
after addition of the cofactor. The traces where the flavin is becoming more reduced are solid and where it 
is returning to the oxidized state at later times are dashed. These demonstrate the slow binding of NADPH 
by the enzyme and formation of the C4α-hydroperoxyflavin intermediate. 
 
 
3.2.7 Reaction Mechanism 
 
 The biochemical analysis and crystal structure described in the previous sections led us to 
propose a reaction mechanism for the N-hydroxylation catalyzed by FrbG (Figure 3.11). Similar 
to other characterized N-hydroxylases, the cofactor NADPH must first enter the enzyme and 
function as an electron donor. In typical FMOs, addition of molecular oxygen occurs 
immediately in the absence of substrate, forming the C4α-hydroperoxyflavin intermediate. 
However, the UV-vis spectroscopic analysis of FrbG suggested this was not the case as indicated 
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by the slow formation of the intermediate and susceptibility towards NADPH oxidase activity. 
The crystallographic structure of FrbG-NADPH-FAD complex also demonstrates the existence 
of a stable “pre-hydride transfer” intermediate, which was consistent with our inability to obtain 
a fully reduced FrbG. As a result, we conclude that there must be an equilibrium between the 
“pre-hydride transfer” and “post-transfer” conformations. 
 Once the hydride transfer occurs from the C4 of NADPH to the N5 atom of the 
isoalloxazine ring of FAD, the oxidized NADP
+
 cofactor is typically shifted to facilitate the 
stabilization of the C4α-hydroperoxyflavin by shielding the active site and providing a suitable 
hydrogen-bonding environment for the intermediate in known FMOs. In stark contrast, FrbG 
displaces the cofactor completely from the binding pocket in order to accommodate the CMP-5’-
3APn substrate. The lack of substrate binding pocket within the active site in the FrbG-NADPH-
FAD complex and inhibition of the initial velocity with increasing concentrations of the substrate 
support this conclusion. Interestingly, the cofactor displacement must be fast enough that the 
C4α-hydroperoxyflavin intermediate does not decay. 
 Nucleotide recognition by the NADPH and substrate binding sites of FrbG contributes to 
the tight specificity in that the substrate must be of the appropriate length to access the C4α-
hydroperoxyflavin intermediate within the channel for catalysis to occur. Once the CMP-5’-
3APn substrate is bound in the enzyme, molecular oxygen is rapidly transferred onto the 
substrate. Following the N-hydroxylation of the substrate, a water molecule is released and 
FADH2 is oxidized to FAD in preparation for another catalytic cycle. 
 79 
 
 
Figure 3.11 Proposed catalytic mechanism of FrbG. Slow flavin reduction by the cofactor NADPH 
allowed for the “pre-hydride transfer” confirmation of the enzyme to be solved. Acceptance of molecular 
oxygen to form the C4α-hydroperoxyflavin intermediate occurs in the presence of bound substrate, rather 
than the cofactor NADP
+
. 
 
 
3.3 Discussion 
 
 FrbG was identified during the cloning and sequencing of the biosynthetic gene cluster 
for the phosphonate antibiotic FR-900098 from Streptomyces rubellomurinus. Although no 
function was originally proposed in the biosynthetic pathway due to low homology to known 
enzymes, it was later confirmed to perform the N-hydroxylation of CMP-5’-3APn yielding the 
hydroxylamine CMP-5’-H3APn. The crystal structure of FrbG-FAD-NADPH revealed a two 
domain architecture with each domain harboring nucleotide binding motifs capable of anchoring 
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the prosthetic group (FAD) and stabilize the cofactor (NADPH) required for catalysis. Based on 
the structure, there was no binding pocket for the substrate, meaning that latter domain must bind 
both the cofactor and substrate. Kinetic analysis of FrbG demonstrated its very tight substrate 
specificity, in particular its use of cofactor and substrate recognition via the nucleotide moiety of 
each. Furthermore, substrate inhibition was monitored as the concentration of CMP-5’-3APn 
increased, indicating the competition by NADPH and substrate for the same binding pocket.  
 The crystal structure solved contained FAD and NADPH, representing the first structure 
of a “pre-hydride transfer” conformation of a flavin monooxygenase. Immediate cracking of the 
crystals resulted upon soaking with NADP
+
, indicating that FrbG undergoes significant 
conformational changes upon reduction of the flavin and subsequent release of the oxidized 
cofactor. This has several consequences for the proposed catalytic cycle of FrbG. For one, the 
fact that the enzyme is in the “pre-hydride transfer” conformation requires there to be an 
equilibrium that favors NADPH rather than NADP
+
. This could partially explain the poor overall 
catalytic efficiency of the enzyme compared to other N-hydroxylases. Additionally, as indicated 
by our UV-vis spectroscopic analysis, the C4α-hydroperoxyflavin intermediate was only formed 
after long incubation times. This led us to propose that molecular oxygen is unable to enter the 
active site of FrbG until the enzyme has displaced NADP
+
 and has CMP-5’-3APn present in the 
binding pocket. This was further confirmed with the position of Asn-58 and its mutational 
analysis; this residue serves the crucial role of providing molecular oxygen to the intermediate. 
Reaction with molecular oxygen to form the C4α-hydroperoxyflavin intermediate without 
stabilization by NADP
+
 makes FrbG very susceptible to NADPH oxidation and exposure to high 
levels of H2O2. Kinetic experiments varying the molecular oxygen level and CMP-5’-3APn 
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substrate levels in solution would be able to further validate the binding order of the two in the 
proposed catalytic mechanism. 
 
 
3.4 Conclusions and Outlook 
 
 Following an in vitro reaction catalyzed by FrbG, a compound corresponding to the 
nitroso derivative (m/z 457→322) of the hydroxylamine product was observed on LC-MS by 
Ryan Cobb. The new product CMP-5’-3-nitrosopropylphopshonate (CMP-5’-3NPn) could arise 
through a second N-hydroxylation cycle, producing a dihydroxy intermediate (m/z 475→322), 
followed by a spontaneous dehydration (Figure 3.12). Exposure to air caused a rapid conversion 
to the nitroso compound, occurring even after FrbG was removed from the reaction mixture
17
. 
This non-enzymatic oxidation has been observed for other hydroxylamine compounds
29
. Purified 
CMP-5’-3NPn was able to be converted back to the hydroxylamine CMP-5’-H3APn by 
anaerobic reduction using samarium iodide (Sm(II)I2)
30
. The formation of the nitroso compound 
represents another potential dead-end within the FR-900098 biosynthetic pathway, although its 
presence within the E. coli production strain has yet to be observed. CMP-5’-3NPn may only be 
an effect of FrbG in vitro reaction conditions and not a concern for subsequent efforts in pathway 
engineering in E. coli. 
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Figure 3.12 FrbG is able to perform a second N-hydroxylation reaction, converting CMP-5’-H3APn (m/z 
459→322) to a dihydroxy intermediate (m/z 475→322). Exposure to air rapidly produces the 
corresponding nitroso compound CMP-5’-3NPn (m/z 457→322). The spontaneous dehydration was 
determined to be non-enzymatic. CMP-5’-3NPn, CMP-5’-3-nitrosopropylphosphonate. 
 
 Several questions still remain as to how the NADPH binding domain of FrbG is capable 
of recognizing both the NADPH cofactor and CMP-5’-3APn substrate. Although the two 
compounds share some structural similarities, there are some significant differences. In 
particular, NADPH contains an additional phosphate group on the 2’ carbon of the adenosine 
ribose, whereas CMP-5’-3APn does not. FrbG had a clear preference for NADPH as a cofactor 
compared to NADH, even though the latter has more structural similarity to the substrate. 
Another interesting feature of the enzyme is that it must also be able to accept both the larger 
adenosine purine ring of NADPH and the smaller cytosine pyrimidine ring of CMP-5’-3APn. 
The enzyme FrbH demonstrated no activity towards the substrate adenosine-5’-triphosphate 
(ATP) as part of the nucleotide transferase reaction. We believe the predominant function of 
nucleotide conjugation in the later steps of FR-900098 biosynthesis is for substrate recognition, 
most critical for FrbG
2
. As a result, the enzyme may have increased activity on AMP-5’-3APn as 
 83 
a substrate compared to CMP-5’-3APn. However, ATP plays a crucial role for intracellular 
energy transfer
31
; its use as a substrate in the FrbH reaction would draw this valuable cofactor 
away from a numerous reactions vital to primary metabolism. Although the docking model has 
provided some insight as to how FrbG binds both NADPH and CMP-5’-3APn, a structure 
containing the substrate would help us better understand the similarities and differences in 
bonding between the cofactor and substrate. Efforts by Professor Satish Nair’s laboratory at the 
University of Illinois in obtaining the FrbG co-crystal structure are currently underway. 
 
 
3.5 Materials and Methods 
 
3.5.1 Materials 
 
 Escherichia coli BL21(DE3) and vector pET28a were purchased from Novagen 
(Madison, WI). The compounds CMP-5’-3APn and CMP-5’-Ac3APn were enzymatically 
synthesized using (±)-2-amino-4-phosphonobutyric acid (2APn) (A1910), cytidine-5'-
triphosphate (CTP) (C1506), and acetyl coenzyme A (AcCoA) (A2181), which were purchased 
from Sigma-Aldrich (St. Louis, MO).  The compound 3-aminopropylphosphonic acid (3APn) 
was purchased from Acros Organics (Morris Plains, NJ).  The cofactor NADPH was purchased 
from Jülich Chiral Solutions GmbH (Jülich, Germany).  Oligonucleotide primers were obtained 
from Integrated DNA Technologies (Coralville, IA). Phusion
®
 High-Fidelity DNA polymerase, 
antarctic phosphatase, T4 DNA ligase, all restriction enzymes, and protein size markers were 
purchased from New England Biolabs (NEB) (Beverly, MA). PCRs were performed with 
FailSafe
™
 PCR PreMix buffer G from Epicentre Biotechnologies (Madison, WI). The QIAprep 
spin plasmid miniprep kit and QIAquick gel extraction kit were purchased from Qiagen 
(Valencia, CA). TALON
®
 Superflow Co
2+
 immobilized metal affinity resin was purchased from 
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Clontech Laboratories (Mountain View, CA). SDS-PAGE gel materials, electrophoresis 
equipment, and size exclusion standards were purchased from Bio-Rad (Hercules, CA). All other 
reagents and materials were purchased from either Sigma-Aldrich or Fisher Scientific 
(Pittsburgh, PA). 
 
3.5.2 Cloning, Expression, and Purification of FrbG 
 
 The original cloning of frbG from fosmid 4G7 was similar to that of Eliot et al. and was 
performed by Dr. Tyler Johannes
1
. Briefly, the gene was PCR amplified using primers 
containing NdeI and HindIII restriction sites and cloned into the corresponding sites of pET28a, 
creating an N-terminal His6-tag.  The primers used for cloning of the gene were: frbG-for-NdeI 
5’-GCTATTAATCATATGACGCACTACGCGACCGTCATCTG-3’ and frbG-rev-HindIII  
5’-CGAAATATAAGCTTTCAACGCCCATCCTCCGTACGATC-3’, where the corresponding 
restriction sites are underlined and italicized.  
 E. coli BL21(DE3) cells overexpressing frbG (HZ19) were grown in Luria-Bertani (LB) 
medium supplemented with kanamycin (50 µg mL
-1
). Cells were grown at 37°C to OD600~0.7 
and then induced at 22°C by the addition of IPTG to a final concentration of 0.3 mM. The 
culture was incubated at 22°C for an additional 18 hours, after which the cells were harvested by 
centrifugation (10 minutes at 10,000 x g) and resuspended in 20 mM Tris-HCl (pH 7.65), 15% 
glycerol, and 0.5 M NaCl (buffer A).  Lysozyme (1 mg mL
-1
) was added to the resuspended cells 
and the sample was freeze-thawed. The cells were further lysed by sonication (Fisher Scientific 
Model 500 Ultrasonic Dismembrator) with the amplitude set at 40% and with a pulse sequence 
of 5 seconds on and 10 seconds off, for 5 minutes. The cell debris was removed by centrifugation 
(15 minutes at 15,000 x g). The N-His6-tagged-proteins were purified using immobilized metal 
affinity chromatography (IMAC) coupled with fast performance liquid chromatography (FPLC). 
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TALON
™
 Superflow Co
2+
 resin was charged and equilibrated according to the manufacturer’s 
instructions. The clarified supernatant was loaded onto the resin and washed with buffer A. 
Contaminating E. coli proteins were washed off the column with buffer A plus 10 mM 
imidazole. Protein was eluted from the column with buffer A plus 0.2 M imidazole. Elution 
fractions were monitored at wavelength of 280 nm. Protein was concentrated using a Millipore 
Amicon Ultra-15 Centrifugal Filter Device (MWCD 10 kDa) at 4,000 rpm at 4°C, washed three 
times with 50 mM HEPES-Na
+
 buffer (pH 7.25), and concentrated again. SDS-PAGE gel 
electrophoresis was used to assess the presence and purity of FrbG in the sample. Concentrated 
protein was stored at -80°C in 20% glycerol. 
 
3.5.3 Determination of Quaternary Structure 
 
 The quaternary structure of native FrbG was determined using an Agilent 1100 series 
HPLC system (Agilent, Palo Alto, CA).  A 300 x 7.8 mm Bio-Sil SEC-250 column (Bio-Rad, 
Hercules, CA) was used with a mobile phase of 0.1 M Na2HPO4, 0.15 M NaCl, and 0.01 M 
NaN3 (pH 6.8) and flow rate of 1 mL min
-1
. A Bio-Rad size exclusion standard was used to 
generate the calibration curve. 
 
3.5.4 Site-directed Mutagenesis 
 
 A megaprimer PCR method was utilized to introduce site-specific mutations into the frbG 
gene using pET28a-frbG plasmid as the template
32
. The original cloning primers frbG-for-NdeI 
and frbG-rev-HindIII were used in combination with one of the mutagenic primers listed in 
Table 3.2. The megaprimer was first amplified using the mutagenic (forward) primer and reverse 
cloning primer, and then extracted and purified from the agarose gel after DNA electrophoresis. 
A second PCR amplified the full-length gene using the forward cloning primer and the 
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megaprimer from the previous reaction. The correctly sized gene was gel extracted and then 
digested with NdeI and HindIII. The digested mutant gene was ligated into dephosphorylated 
plasmid pET28a which was digested with the same two restriction enzymes. Chemically 
competent E. coli BL21(DE3) were transformed with the ligation mixtures by heat shock 
treatment and grown on LB plates supplemented with kanamycin (50 µg mL
-1
). Several colonies 
were picked and clones were checked by digestion analysis to ensure the correctly sized gene 
was present. Purified plasmids were submitted to ACGT, Inc. (Wheeling, IL) for sequencing to 
confirm the desired mutation as well as eliminate the chance of introducing random mutations 
during either of the PCR steps. Final constructs contained His6-tags making them amenable to 
purification by IMAC coupled to FPLC as described in Section 3.5.2. 
 
Table 3.2 Primer sequences used in site-directed mutagenesis. Mutated codons are italicized. 
 
Site Sequence 
Megaprimer 
Length (bp) 
N58A GGGATCCGCGCC GCC TCGCTGGGCTCG 1155 
H221A CTCGGCGGCGCC GCC AGCGCCTGGGCG 666 
R250A ACGGTGGTCGAG GCC CGGCTGCCGCCG 579 
 
 
 
3.5.5 Kinetic Analysis 
 
 Experiments used to determine the kinetic parameters of FrbG were carried out in 
triplicate in one of two ways; the first of which measured enzymatic activity by consumption of 
the cofactor NADPH. Each reaction mixture (100 µL final volume) contained 1 μM FrbG in 50 
mM HEPES-Na
+
 buffer (pH 7.25). For the determination of substrate kinetic parameters, the 
NADPH concentration was held constant at 300 μM while the specified substrate concentration 
of compounds CMP-5’-3APn and CMP-5’-Ac3APn ranged from 0-200 μM, while that of 
compounds 3APn and Ac3APn ranged up to 2 mM. For the determination of KM with NADPH, 
the CMP-5’-3APn concentration was held constant at 100 μM while the final concentration of 
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NADPH ranged from 0-100 μM. All reactions were initiated by the addition of NADPH and run 
at 30°C. Enzymatic activity was monitored by the decrease in absorbance at 340 nm using a 
Varian Cary 100 Bio UV-visible spectrophotometer (Varian, Palo Alto, CA). 
 Kinetic parameters of FrbG were also determined by tracking hydroxylated product 
formation by LC-MS. Each reaction mixture (100 µL final volume) contained 1 μM FrbG and 
300 μM NADPH in 50 mM HEPES-Na+ buffer (pH 7.25). The concentration of CMP-5’-3APn 
substrate ranged from 0-750 μM in these assays. All reactions were initiated by the addition of 
recombinant FrbG and run at 30°C. Aliquots were taken and quenched by the addition of 4% 
trifluoroacetic acid and were kept at 4°C until analysis by HPLC. The extracted ion 
chromatograms of hydroxylated product formation were measured by LC-MS analysis. The data 
were used to fit the substrate inhibition model of enzyme kinetics in GraphPad Prism 5 
(GraphPad Software, La Jolla, CA) in order to obtain kinetic parameters of FrbG, including the 
inhibition constant KI. 
 A modified protocol to the kinetic analysis by NADPH oxidation described above was 
used to determine the activity of the FrbG mutants N58A, H221A, and R250A. Each reaction 
mixture (100 µL final volume) contained 5 μM FrbG (or mutant) in 50 mM HEPES-Na+ buffer 
(pH 7.25). NADPH oxidase activity assays contained only 300 μM NADPH; whereas, samples 
measuring substrate hydroxylation contained 300 μM NADPH and 250 μM CMP-5’-3APn. All 
reactions were initiated by the addition of NADPH and run at 30°C. Enzymatic activity was 
monitored by the decrease in absorbance at 340 nm. 
 
3.5.6 LC-MS Analysis 
 
 Products of the enzymatic reactions were analyzed by an Agilent 1100 series LC/MSD 
XCT plus ion trap mass spectrometer (Agilent, Palo Alto, CA) at the Roy J. Carver 
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Metabolomics Center at the University of Illinois (Urbana, IL).  The liquid chromatography (LC) 
was performed using an Agilent 1100 series HPLC equipped with an online degasser, binary 
pump, and autosampler.  The mass spectrometry (MS) was performed using an Agilent XCT ion 
trap MSD mass spectrometer.  The MS system was operated using a drying temperature of 
350°C, a nebulizer pressure of 35 psi, a drying gas flow of 8.5 L min
-1
, and a capillary voltage of 
4500 V.  For the CMP-containing compounds, analytes were resolved on a 150 × 4.6 mm C18 
reverse-phase HPLC column (Agilent, Palo Alto, CA).  HPLC parameters were as follows: 
solvent A: 15 mM ammonium formate; solvent B: 20 mM ammonium acetate; 25% solvent B at 
0 minutes; gradient 100% solvent B in 10 minutes, and 100% solvent B for 3 minutes; flow rate: 
0.3 mL min
-1
; detection by UV absorbance at 254 nm.  Mass spectra were acquired in ultra scan 
mode using electrospray ionization (ESI) with negative polarity.  For the non-CMP-containing 
compounds, analytes were resolved on a 100 x 4.6 mm Synergi 4u Fusion-RP 80A analytical 
column (Phenomenex, Torrance, CA).  HPLC parameters were as follows: solvent A: 0.1% 
formic acid in ddH2O; solvent B: 100% acetonitrile; gradient of 0 to 40% solvent B for 10 
minutes, a gradient of 40 to 100% solvent B for 3 minutes, and 100% solvent B for 5 minutes; 
flow rate of 200 µL min
-1
.  Mass spectra were acquired in ultra scan mode using electrospray 
ionization with positive polarity. 
 
3.5.7 Isolation of C4α-Hydroperoxyflavin Intermediate 
 
 The C4α-hydroperoxyflavin intermediate was monitored using a Varian Cary 100 Bio 
UV-visible spectrophotometer (Varian, Palo Alto, CA) with the block temperature held at 4°C. 
Aerobic assays were performed by adding 7 µM purified FrbG to aerated 50 mM HEPES-Na
+
 
buffer (pH 7.25). Formation of the C4α-hydroperoxyflavin intermediate was then initiated with 
the addition of 7 µM NADPH (or 10-fold excess). Wavelength scans from 300 to 550 nm were 
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taken at specific time points. Anaerobic assays were performed with a sealed septum cap cuvette 
and all solutions were mixed inside of an anerobic chamber. 7 µM purified FrbG was first added 
to degassed 50 mM HEPES-Na
+
 buffer (pH 7.25). In one case, 10-fold excess oxidized NADP
+
 
was included at this point in attempts to stabilize the C4α-hydroperoxyflavin intermediate. 
Formation of the intermediate was then initiated with the addition of degassed 7 µM NADPH (or 
10-fold excess). 
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Chapter 4: Characterization and Application of the Fe(II) and  
α-Ketoglutarate Dependent Hydroxylase FrbJ 
 
 
4.1 Introduction 
 
 As detailed in Chapter 2, all genes within the putative FR-900098 gene cluster from 
Streptomyces rubellomurinus were assigned a role in FR-900098 biosynthesis with the exception 
of frbJ. The enzyme is homologous to Fe(II) and α-ketoglutarate (αKG) dependent hydroxylases, 
which catalyze substrate hydroxylation with concomitant oxidative decomposition of αKG to 
succinate and carbon dioxide
1
. Enzymes within this family play a pivotal role in protein 
modification
2-4
, repair of alkylated DNA/RNA
5-6
, lipid metabolism
7-8
, and several other types of 
reactions
9-10
. They also catalyze a diverse set of reactions in antibiotic synthesis where they 
generate pathway precursors, intermediates, and final products
1
. For example, clavaminate 
synthase (CAS) catalyzes three independent oxidative reactions in the biosynthesis of clavulanic 
acid
11
. Interestingly, another enzyme from this family has demonstrated an epoxidase activity in 
the semisynthetic pathway for the phosphonate antibiotic fosfomycin. The enzyme encoded by 
epoA from Penicillium decumbens converts the substrate cis-propenylphosphonic acid to the 
final compound fosfomycin
12
. Although the natural function for this enzyme in the native host is 
unknown, the epoxidase activity signifies the broad range of activity and function of Fe(II) and 
αKG dependent enzymes. 
 Deletion studies of frbJ within the heterologous hosts Streptomyces lividans and 
Escherichia coli indicated that the enzyme was not required for FR-900098 biosynthesis, leading 
to some uncertainty as to its function
13-14
. It was originally postulated that FrbJ might be 
responsible for the N-hydroxylation step; however, catalysis of this nature by this class of 
enzyme would have been exceedingly rare. Fe(II) and αKG dependent enzymes can efficiently 
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catalyze the hydroxylation of inactivated C-H bonds, so we investigated whether FrbJ might be 
involved in the synthesis of another phosphonate antibiotic FR-33289 ((R)-2-hydroxy-3-(N-
acetyl-N-hydroxyamino)propylphosphonic acid)
15-16
. Production of this compound was observed 
in both the native producer S. rubellomurinus and a heterologous S. lividans 4G7 host
14
. This 
chapter will focus on the expression, purification, and biochemical characterization of FrbJ and 
the determination of its role in FR-900098 biosynthesis. We will also demonstrate its ability to 
catalyze the hydroxylation of additional substrates as part of the creation of a new library of 
potential antimalarial drugs, all of which were screened for improved antimalarial activity. 
 
 
4.2 Results 
 
4.2.1 Biochemical Analysis 
 
 The full-length frbJ gene (1020 bp) was cloned from fosmid 4G7 into pET28a, creating 
an N-terminal His6-tag. E. coli BL21(DE3) cells were transformed with this construct and lysates 
of IPTG-induced cultures were analyzed by SDS-PAGE to check for the presence of soluble 
protein
17
. A clear overexpression band for FrbJ was detected, which constituted approximately 
60% of the total soluble cellular protein (Figure 4.1). The His6-tag allowed for the single step 
purification of the enzyme using immobilized metal affinity chromatography (IMAC) with 
TALON Superflow Co
2+
 resin coupled with fast performance liquid chromatography (FPLC). 
The purity of FrbJ (39.9 kDa) was also analyzed by SDS-PAGE (Figure 4.1) and was greater 
than 95%. The concentration of final enzyme stocks was determined by the Bradford method
18
 
and an estimated extinction coefficient of 48.3 mM
-1
 cm
-1
 at 280 nm (San Diego Supercomputer 
Center Biology WorkBench [http://workbench.sdsc.edu])
19
, each providing similar results.   
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Figure 4.1 Overexpression and purification of recombinant FrbJ in E. coli BL21(DE3). Lane M, protein 
standard (kDa); lane 1, cell-free lysate of empty pET28a; lane 2, cell-free lysate of induced FrbJ culture; 
lane 3, purified FrbJ enzyme.  
 
 
 Based on its homology to known Fe(II) and α-ketoglutarate dependent hydroxylases, we 
believed FrbJ might be involved in the biosynthesis of another phosphonate antibiotic, FR-
33289. This compound has similar antibacterial properties in comparison to FR-900098 and has 
the potential to be another effective antimalarial compound
15
. Thus, we began to investigate 
whether FrbJ could utilize FR-900098 as a substrate in an enzymatic conversion to FR-33289. 
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Figure 4.2 Analysis of the FrbJ reaction product by LC-MS. Negative control contains heat-inactivated 
enzyme. Extracted ion chromatograms (m/z 214→154) of the two reactions show that FrbJ is able to 
convert FR-900098 to FR-33289. This figure was reprinted with permission from Elsevier Journals. 
Copyright © Chemistry and Biology, 17, 57-64 (2010). 
 
 
 After incubating purified FrbJ with FR-900098, α-ketoglutarate, Fe(II)SO4, and ascorbic 
acid, we were able to monitor conversion to FR-33289 on LC-MS (Figure 4.2). The product was 
absent in the negative control, which indicates that FrbJ was responsible for the enzymatic 
reaction
14
. Mixtures lacking either αKG or iron were also not able to catalyze the reaction, 
demonstrating the need for addition of these cofactors to the in vitro reaction (Figure 4.3). 
Expression of frbJ along with the remaining genes in the pathway could provide a means for 
production of the phosphonate FR-33289. 
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Figure 4.3 Hydroxylase activity of FrbJ. 
 
 
4.2.2 Structure and Reaction Mechanism 
 
 The structure of full-length FrbJ was solved by Dr. Houjin Zhang in Professor Satish 
Nair’s laboratory at the University of Illinois to a resolution of 1.8 Å. Unfortunately, the active 
site of the enzyme was unresolved so further docking studies were not feasible. Despite the 
uncertainty in the binding pocket, the core structure of FrbJ was shared by other Fe(II) and aKG-
dependent hydroxylases, possessing a β-strand “jellyroll” structural fold1. This family of 
enzymes also contain three conserved metal-binding protein residues in a His
1
-X-Asp/Glu-Xn-
His
2
 motif, otherwise known as the 2-His-1-carboxylate facial triad
20
. Based on sequence 
homology, the residues His-150, Glu-152, and His-228 correspond to the facial triad of FrbJ. 
There is nearly identical arrangement of the three amino acid side chains among all enzymes of 
this class, which coordinate with the Fe(II) ion in the active site. The facial triad of FrbJ was 
modeled after taurine dioxygenase, TauD (PDB structure 1GQW)
21-22
. This model shows 
coordination with the Fe(II) center as well as the cofactor αKG (Figure 4.4). 
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Figure 4.4 Model of 2-His-1-carboxylate facial triad in FrbJ. Fe(II) center is coordinated with amino acid 
side chains of His-150, Glu-152, and His-288 as well as α-ketoglutarate (αKG) cofactor. 
 
 
 The Fe(II) center of the 2-His-1-carboxylate facial triad is typically six-coordinate at the 
beginning of the catalytic cycle with the three amino acid side chains and three solvent 
molecules. At this point, the iron is relatively unreactive towards O2. It is only until cofactor and 
substrate binding to the active site of the enzyme that the metal center becomes prepared to bind 
O2, thus promoting strong coupling between the O2 reduction and substrate oxidation
20
. The 
primary substrate of the reaction, FR-900098 in the case of FrbJ, does not actually bind to the 
metal center of the enzyme at any point
1
. It will remain in the plane above the facial triad 
whereby αKG is decomposed and O2 is cleaved to yield an Fe(IV)-oxo species. The hydrogen of 
the inactivated C-H bond is then abstracted and hydroxyl radical rebound completes the catalytic 
cycle, yielding the final hydroxylated product
23
. In depth structural and mechanistic studies were 
not performed on FrbJ due to its high homology to already well-known and characterized Fe(II) 
and αKG dependent hydroxylases. 
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4.2.3 Kinetic Analysis 
 
 FrbJ was shown in Section 4.2.1 to be able to catalyze the hydroxylation of FR-900098 to 
produce FR-33289. Kinetic analysis was performed on this substrate as well another putative 
substrate from the FR-900098 biosynthetic pathway and a similar phosphonate antibiotic. As 
demonstrated in Chapter 2, the final steps in the pathway contain a series of intermediates 
conjugated to the nucleotide cytidine-5’-monophosphate (CMP). If hydroxylation by FrbJ were 
to occur before cleavage of the CMP by FrbI, CMP-5’-FR-900098 could serve as the true 
substrate for the enzyme. FrbJ showed activity towards FR-900098 and not the nucleotide 
containing substrate, indicating that nucleotide cleavage must occur before hydroxylation in the 
biosynthetic pathway (Table 4.1). We also checked for enzymatic activity with another known 
phosphonate antibiotic, fosmidomycin (FR-31564). This substrate contains an N-formyl group 
instead of the N-acetyl group on FR-900098. FrbJ demonstrated activity towards this structurally 
similar substrate, but displayed a 6-fold less preference compared to the natural substrate. As a 
result of fosmidomycin hydroxylation by FrbJ, a novel phosphonate was able to be synthesized, 
(R)-2-hydroxy-3-(N-formyl-N-hydroxyamino)propylphosphonic acid, hereby called 
hydroxyfosmidomycin
24
. To the best of our knowledge, this compound has never been detected 
from a biological source or produced synthetically. 
 
Table 4.1 Kinetic parameters of FrbJ. NR: no reaction detected; SD: standard deviation. This table was 
reprinted with permission from The Royal Society of Chemistry. Copyright © Chemical 
Communications, 47, 10025-10027 (2011). 
 
Substrate 
kcat (min
-1
) 
(mean ± SD) 
KM (μM)  
(mean ± SD) 
kcat / KM 
(mM
-1 
min
-1
) 
FR-900098 147 ± 31.1 289 ± 48.1 509 
Fosmidomycin 57.3 ± 8.1 700 ± 137 81.9 
CMP-5’-FR-900098   NR 
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4.2.4 Regulatory Role in FR-900098 Pathway 
 
 Heterologous production of FR-33289 in E. coli was attempted by expressing all of the 
genes in the biosynthetic cluster, excluding frbI (pETDuet-frbABCD, pRSFDuet-frbHFG, 
pACYCDuet-frbEJ-dxrB). Although FR-900098 production was evident in the LC-MS, no 
detectable amounts of FR-33289 were monitored. In order to minimize the impact of the 
remaining genes in the pathway, cell-free lysate of E. coli that only expressed FrbJ was 
incubated with FR-900098. The lysate only demonstrated conversion to FR-33289 upon addition 
of exogenous α-ketoglutarate, suggesting that FrbJ may be regulated by the intracellular 
concentration of this cofactor. 
 The biosynthesis of secondary metabolites can be effectively regulated via the 
availability of precursors, cofactors, and cellular energy originating from primary metabolism. 
Rate-limiting enzymes control the flux of these critical metabolites to ensure secondary 
metabolism does not become favored over primary metabolism. Khetan et al. described the 
function of lysine-6-aminotransferase (LAT), which was determined to be the rate-limiting 
enzyme in cephamycin biosynthesis from Streptomyces clavuligerus
25
. This enzyme, which 
utilizes αKG as a cofactor in the conversion of lysine to α-aminoadipic acid, is the first step in 
the biosynthetic pathway. The authors measured the KM for αKG to be 8.6 mM, substantially 
higher than its intracellular concentration ranging from 0.3-1.3 mM
25
. The KM value for LAT is 
also higher than that from other characterized Fe(II) and αKG dependent hydroxylases, which is 
typically on the order of 10s of micromolar
26-28
.  
 In the same way LAT regulates the cephamycin biosynthetic pathway, we believe FrbJ 
can regulate the ratio of the two phosphonates FR-900098 and FR-33289 using α-ketoglutarate. 
The KM for FrbJ with its cofactor was calculated to be 1.3 ± 0.19 mM, comparably to the high 
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KM of LAT and close to the value of intracellular level of αKG. We believe a similar regulation 
mechanism is present in FR-900098 biosynthesis in S. rubellomurinus, except for one crucial 
difference. The entire cephamycin biosynthesis can be regulated by the intracellular 
concentration of αKG since LAT is the first enzyme in the pathway, making the high KM of the 
enzyme ideal for switching the biosynthesis of cephamycin entirely on or off. The lower KM of 
FrbJ is a much weaker control valve, ideal for slower and less complete conversions of FR-
900098 to FR-33289
24
. 
 
4.2.5 Investigation of FR-33289 
 
  FR-33289 was originally isolated from the same Streptomyces rubellomurinus strain that 
produced FR-900098. Initial antibiotic assays demonstrated that these two phosphonates 
exhibited a similar range of potencies, showing activity against many different organisms 
including Pseudomonas, Salmonella, and E. coli
15
. However, the capacity of FR-33289 to 
function as an antimalarial was never assessed. Based on the similar structure of the two 
compounds, it was expected that FR-33289 will also be able be a specific inhibitor of 1-deoxy-D-
xylulose-5-phosphate reductoisomerase (Dxr). Since FrbJ has allowed a biosynthetic route for 
the production of FR-33289, we sought to determine if it was another antimalarial compound. 
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Figure 4.5 Growth inhibition assays of (A) E. coli HZ832 (FR-900098-sensitive strain) and (B) E. coli 
HZ1015 (FR-900098-resistant strain). Discs labeled 1 were soaked with ddH2O; discs labeled 2 were 
soaked with FR-900098; and discs labeled 3 were soaked with FR-33289.  The FR-900098-sensitive 
strain produced inhibition zones for both FR-900098 and FR-33289, while the FR-900098-resistant strain 
(containing pMal-c2x-dxrB) did not produce inhibition zones for either phosphonate. 
 
 
 Professor William Metcalf’s laboratory at the University of Illinois engineered an E. coli 
strain hypersensitive to phosphonate antibiotics and was used in all bioassays
13
. The strain 
WM6242 contains three component phosphonate uptake genes phnCDE, each under an IPTG 
inducible promoter. Bioassay plates with the FR-900098-sensitive strain (HZ832) showed clear 
inhibition zones around discs impregnated with FR-900098. Target specificity was then 
examined using two FR-900098-resistant strains. These strains contained either pMal-c2x-dxrB 
(HZ1015) or pMal-c2x-ispC (HZ1016), the immunity gene from the FR-900098 biosynthetic 
cluster that encodes a target homolog or the target enzyme from E. coli, respectively. These two 
resistant strains showed no growth inhibition by FR-900098. An equal amount of FR-33289 was 
also impregnanted on each of the bioassay plates. Identical behavior was seen for FR-33289 in 
comparison to FR-900098, indicating that this compound is also a potent antimalarial compound 
(Figure 4.5)
24
. Overall, these bioassays are qualitative in nature. A quantitative assessment of the 
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potency of FR-33289 compared to the known antimalarials FR-900098 and fosmidomycin using 
purified Dxr enzyme will be discussed further in Section 4.2.7. 
 
4.2.6 Directed Biosynthesis using FrbJ and DhpI 
 
 The dianionic charge of phosphonates at physiological pH poses two potential problems 
for the efficacy of these antibiotics. First, they become less than ideal mimics of carboxyl groups 
and their tetrahedral intermediates, although this problem is negligible for FR-900098 since the 
compound mimics a phosphate ester. Second, phosphonates also suffer from poor bioavailability 
as a result of their high polarity, which is a serious concern for FR-900098 and fosmidomycin. 
The oral bioavailability of both compounds is only moderate with a resorption rate of 
approximately 30% due to their low lipophilicity
29
. 
 Recent research efforts have been focused on masking the charged moiety of the 
phosphonate group through esterification. The Jomaa and Schlitzer laboratories have published 
several papers on the chemical synthesis of FR-900098 prodrugs that have increased the 
bioavailability of the compound. They began with a series of diaryl ester prodrugs of FR-900098, 
many of which showed increased bioactivity. The newly synthesized prodrugs were able to cross 
the gastrointestinal tract into the blood stream with higher efficiency. Once in the blood plasma, 
the compounds were cleaved by broad specificity plasma esterases, thus releasing the free and 
active phosphonate
30
. Despite the improvement in oral efficacy of the diaryl ester prodrugs, there 
was concern as to the release of phenol derivatives through the processing of the compounds. As 
an alternative, these laboratories synthesized a series of acyloxyalkyl ester prodrugs. These 
compounds proved just as effective in the treatment of malaria in mice and released less toxic 
byproducts compared to their predecessors
31-32
. All of these esterified compounds demonstrated 
no inhibition on purified Dxr enzyme; any improvements in efficacy were directly from the 
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facilitation of uptake into the blood stream. We sought a method for the preparation of similar 
esterified FR-900098 prodrugs though biosynthetic means. 
 Dehydrophos, a tripeptide phosphonate analog produced by Streptomyces luridus, 
contains a methyl ester of a phosphonodehydroalanine group. The gene cluster for this antibiotic 
contains an S-adenosyl-L-methionine (SAM) dependent O-methyltransferase encoded by dhpI
33
. 
The enzyme was cloned and characterized by Dr. Jin-Hee Lee in Professor Wilfred van der 
Donk’s laboratory at the University of Illinois34. DhpI has very low substrate specificity, and is 
able to catalyze the O-methylation of a wide range of phosphonate substrates, making it an 
excellent candidate for further engineering (Figure 4.6). 
 
 
 
Figure 4.6 Reaction scheme for O-methylation by DhpI. Enzyme is able to catalyze the esterification of a 
broad range of phosphonate substrates. DhpI, like many other methyltransferases, undergoes product 
inhibition by the product S-adenosylhomocysteine (SAH)
35
. As a result, SAH nucleosidase, which 
catalyzes SAH hydrolysis to adenine and S-ribosylhomocysteine, is added to in vitro reaction mixtures to 
ensure complete conversion to the desired methylated phosphonate. 
 
 
 As previously described, FrbJ was capable of catalyzing the β-hydroxylation of FR-
900098 and fosmidomycin to produce FR-33289 and hydroxyfosmidomycin, respectively. These 
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four phosphonates were used as the basis for the creation of a prospective antimalarial library; 
each was methylated by DhpI (Figure 4.7). FR-900098 and fosmidomycin were commercially 
available and the subsequent six compounds were synthesized by in vitro reactions with purified 
FrbJ, DhpI, and Pfs. The phosphonate library was then purified to remove any unreacted 
substrate or cofactors
24
. Although not identical to the double ester prodrugs prepared by chemical 
synthesis, these methylated compounds may enhance the bioavailability of the final active 
phosphonate drugs. 
 
 
 
Figure 4.7 Prospective antimalarial library created using FrbJ and DhpI (with Pfs). Due to the low 
substrate specificity of DhpI, hydroxylation by FrbJ was completed before O-methylation. 
 
 
4.2.7 Antimalarial Library Screening 
 
 The antimalarial library was first screened by bioassays of the E. coli phosphonate uptake 
strains. Bioassay plates of the FR-900098-sensitive strain showed clear inhibition zones around 
discs impregnated with FR-900098, FR-33289, fosmidomycin, and hydroxyfosmidomycin; all of 
which were lost with the resistant E. coli strain. However, there was no detectable growth 
inhibition for any of the corresponding methylated compounds on the FR-900098-sensitive 
strain. To ensure the lack of bioactivity on the plate was not specific for the Dxr target, we 
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utilized a second phosphonate with a completely different target. Fosfomycin, a broad-range 
antibacterial used to treat urinary tract infections
36
, and the corresponding fosfomycin-OMe was 
prepared in a similar method as the other phosphonates. Similar to the prospective methylated 
antimalarials, there was no growth inhibition of the sensitive E. coli strain for fosfomycin-OMe. 
The methyl group is either not cleaved in these in vivo bioassays, preventing the release of the 
active phosphonate, or the methyl ester hampers uptake
24
. 
 
Table 4.2 Antimalarial library screening by inhibition of purified Dxr from Plasmodium falciparum. NI: 
no enzyme inhibition detected; SD: standard deviation. This table was reprinted with permission from 
The Royal Society of Chemistry. Copyright © Chemical Communications, 47, 10025-10027 (2011). 
 
Substrate 
IC50 (nM) 
(mean ± SD) 
KI (nM)  
(mean ± SD) 
FR-900098 15 ± 2.6 3.2 ± 1.0 
FR-33289 16 ± 3.1 3.0 ± 0.8 
Fosmidomycin 36 ± 5.9 6.8 ± 1.6 
Hydroxyfosmidomycin 41 ± 5.3 7.1 ± 1.4 
FR-900098-OMe NI NI 
FR-33289-OMe NI NI 
Fosmidomycin-OMe NI NI 
Hydroxyfosmidomycin-OMe NI NI 
 
 
 
 The antimalarial library was also assessed using purified Plasmodium falciparum Dxr 
(pfDxr). The recombinant enzyme was codon-optimized for heterologous expression in E. coli 
and was designed to lack the N-terminal signal peptide
37-38
. Enzymatic activity was monitored by 
NADPH oxidation at 340 nm, and subsequent inhibition values for the IC50 and KI were obtained 
for each of the prospective antimalarial compounds. Similar to the in vivo bioassays, only the 
free, unmethylated phosphonate compounds demonstrated in vitro inhibition of pfDxr. There was 
no apparent decrease to the enzymatic activity upon addition of the compounds to any of the 
reaction mixtures. The approximately two-fold difference between the inhibition of FR-900098 
and fosmidomycin is similar to published data
37
. Also, the inhibition constants for FR-900098 
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and fosmidomycin with their hydroxylated counterparts, FR-33289 and hydroxyfosmidomycin, 
respectively, were determined to be nearly identical to each other (Table 4.2). Even though the 
natural pfDXR substrate also contains a hydroxyl group similar to FR-33289 and 
hydroxyfosmidomycin, albeit at different positions on the carbon backbone, there was no 
apparent increase in inhibition compared to FR-900098 and fosmidomycin
24
. 
 
 
4.3 Discussion 
 
 FrbJ was identified during the cloning and sequencing of the biosynthetic gene cluster for 
the phosphonate antibiotic FR-900098 from Streptomyces rubellomurinus. This enzyme has high 
homology to Fe(II) and αKG dependent hydroxylases and demonstrated activity towards the 
natural substrate FR-900098 as well as the structurally similar fosmidomycin. However, there 
was no measurable activity with the potential pathway substrate CMP-5’-FR-900098. The crystal 
structure of FrbJ was solved, although the active site of the enzyme was unresolved making 
docking studies impossible. Based on the results of the kinetic analysis, the enzyme would be 
expected to have a constricted binding pocket, making the hydroxylation of the larger nucleotide-
conjugated substrate unachievable. 
 We also investigated the role of FrbJ as a regulatory element in the secondary metabolism 
of these phosphonate antibiotics in S. rubellomurinus. The KM of the cofactor α-ketoglutarate for 
FrbJ is considerably higher compared to other Fe(II) and αKG dependent hydroxylases. 
However, the actual purpose of this regulation mechanism is still unclear. Based on the inhibition 
data with purified pfDxr, there was no statistically significant difference in the inhibition activity 
of FR-900098 and FR-33289. One could imagine that if FR-33289 was the more potent of the 
two, then it would make sense it to be the final product of the entire biosynthetic pathway. On 
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the other hand, if FR-900098 were the more potent of the two, a “safety valve” conversion to 
FR-33289 would be desirable to prevent buildup of the toxic compound. Despite the fact that 
these two phosphonate compounds have similar inhibitory properties with purified pfDxr, one of 
them may be more active against competitors in the ecological niche occupied by S. 
rubellomurinus. Further investigation into this scenario may reveal more about the cofactor-
cased regulation mechanism. 
 Not only does FrbJ control the ratio of FR-900098 and FR-33289 with the high KM for 
αKG, but it also seemingly prevents the heterologous production of FR-33289 in E. coli. Lysate 
only demonstrated activity on FR-900098 upon addition of exogenous αKG. Efforts in metabolic 
engineering would need to be undertaken in order to increase the intracellular levels of αKG high 
enough to obtain substantial production of FR-33289. Alternatively, protein engineering may be 
able to reduce the KM. 
 
 
4.4 Conclusions and Outlook 
 
 Directed biosynthesis was performed with FrbJ and DhpI, the O-methyltransferase from 
the dehydrophos biosynthetic cluster. Beginning with the known antimalarials FR-900098 and 
fosmidomycin, six other compounds were synthesized via in vitro reactions with purified 
enzymes. Bioactivity was only observed for the free, unmethylated phosphonates in both the E. 
coli bioassays and in vitro assays with pfDxr. This raises the question as to why none of the 
esterified phosphonates were able to increase the bioavailability, as was the case in the literature. 
For one, the methylated compounds were not expected to demonstrate bioactivity in vitro, since 
the ester likely blocks an important charge interaction within the binding pocket of pfDxr. The 
lack of activity for the esterified phosphonate in the E. coli phosphonate uptake strain was 
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unexpected, yet could be explained by a series of factors. Although we believed the modified 
compounds would cross into E. coli with higher efficiency, this may not be the case as the 
methyl group could inhibit membrane transfer. If, in fact, the modified phosphonates were able 
to enter E. coli, little is actually known about the esterases that perform the hydrolytic cleavage 
releasing the active compounds. The esterified prodrugs created via chemical synthesis by the 
Jomaa and Schlitzer laboratories facilitated this hydrolytic processing reaction
30-32
, whereas the 
methyl group present in several candidates of our prospective antimalarial library might be a 
worse leaving group in the reaction. Finally, the human esterases that cleaved the synthetic esters 
in the blood plasma could be significantly different to those in the E. coli used in the bioassays. 
One or a combination of these factors could explain why no inhibition was detected for the 
methylated compounds in our antimalarial library. 
 The directed biosynthesis with FrbJ was successful in producing two new antimalarial 
target compounds, FR-33289 and hydroxyfosmidomycin. The E. coli bioassays showed some 
improvement for these hydroxylated compounds as the zones of inhibition were slightly larger. 
Although the inhibition of the Dxr enzyme itself does not change, the bioavailability of these 
compounds appears to increase. In order to more accurately assess these compounds, we have 
expanded the scope of the inhibition assays. Further experiments are currently ongoing in 
collaboration with Professor Wesley Van Voorhis’s laboratory at the University of Washington 
to screen for inhibition in Plasmodium. 
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4.5 Materials and Methods 
 
4.5.1 Materials 
 
 Escherichia coli BL21(DE3) and vector pET28a were purchased from Novagen 
(Madison, WI). Overexpression strains for DhpI and Pfs (SAH nucleosidase) were kindly 
provided by Professor Wilfred van der Donk at the University of Illinois (Urbana, IL). The 
compounds α-ketoglutarate (αKG) (K2010), ferrous sulfate (Fe(II)SO4) (F7002), ascorbic acid 
(A5960), S-(5’-adenosyl)-L-methionine (SAM) (A7007), and fosfomycin (79492) were 
purchased from Sigma-Aldrich (St. Louis, MO). Fosmidomycin was purchased from Invitrogen 
(Carlsbad, CA). FR-900098 was purchased from Toronto Research Chemicals (Toronto, 
Canada). 1-Deoxy-D-xylulose-5-phosphate (DXP) was purchased from Echelon Biosciences 
(Salt Lake City, UT). NADPH was purchased from Jülich Chiral Solutions GmbH (Jülich, 
Germany). TALON
® 
Superflow Co
2+
 immobilized metal affinity resin was purchased from 
Clontech Laboratories (Mountain View, CA). SDS-PAGE gel materials and electrophoresis 
equipment were purchased from Bio-Rad (Hercules, CA). Protein size markers were purchased 
from New England Biolabs (NEB) (Beverly, MA). Blank paper discs (6 mm diameter) were 
purchased from BD Diagnostics (Sparks, MD). All other reagents and materials were purchased 
from either Sigma-Aldrich or Fisher Scientific (Pittsburgh, PA). 
 
4.5.2 Cloning, Expression, and Purification of FrbJ 
 
 The original cloning of frbJ from fosmid 4G7 was similar to that of Eliot et al. and was 
performed by Dr. Tyler Johannes
13
. Briefly, the gene was PCR amplified using primers 
containing NdeI and HindIII restriction sites and cloned into the corresponding sites of pET28a, 
creating an N-terminal His6-tag.  The primers used for cloning of the gene were: frbJ-for-NdeI 
5’-GCTATTAATCATATGGTTGAGATTCTGAAGAAGCCCGTCA-3’ and frbJ-rev-HindIII  
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5’-CGAAATATAAGCTTTCAGTGCGTCGGCTTCGCCGCCG-3’, where the corresponding 
restriction sites are underlined and italicized.  
 E. coli BL21(DE3) cells overexpressing frbJ (HZ5) were grown in Luria-Bertani (LB) 
medium supplemented with kanamycin (50 µg mL
-1
). Cells were grown at 37°C to OD600~0.7 
and then induced at 22°C by the addition of IPTG to a final concentration of 0.3 mM. The 
culture was incubated at 22°C for an additional 18 hours, after which the cells were harvested by 
centrifugation (10 minutes at 10,000 x g) and resuspended in 20 mM Tris-HCl (pH 7.65), 15% 
glycerol, and 0.5 M NaCl (buffer A).  Lysozyme (1 mg mL
-1
) was added to the resuspended cells 
and the sample was freeze-thawed. The cells were further lysed by sonication (Fisher Scientific 
Model 500 Ultrasonic Dismembrator) with the amplitude set at 40% and with a pulse sequence 
of 5 seconds on and 10 seconds off, for 5 minutes. The cell debris was removed by centrifugation 
(15 minutes at 15,000 x g). The N-His6-tagged-proteins were purified using immobilized metal 
affinity chromatography (IMAC) coupled with fast performance liquid chromatography (FPLC). 
TALON
™
 Superflow Co
2+
 resin was charged and equilibrated according to the manufacturer’s 
instructions. The clarified supernatant was loaded onto the resin and washed with buffer A. 
Contaminating E. coli proteins were washed off the column with buffer A plus 10 mM 
imidazole. Protein was eluted from the column with buffer A plus 0.2 M imidazole. Elution 
fractions were monitored at wavelength of 280 nm. Protein was concentrated using a Millipore 
Amicon Ultra-15 Centrifugal Filter Device (MWCD 10 kDa) at 4,000 rpm at 4°C, washed three 
times with 50 mM HEPES-Na
+
 buffer (pH 7.25), and concentrated again. SDS-PAGE gel 
electrophoresis was used to assess the presence and purity of FrbJ in the sample. Concentrated 
protein was stored at -80°C in 20% glycerol. 
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4.5.3 Kinetic Analysis 
 
 Experiments used to determine the kinetic parameters of FrbJ were carried out in 
triplicate. Each reaction mixture (100 µL final volume) contained 0.2 μM FrbJ, 200 μM 
Fe(II)SO4, 800 μM ascorbic acid in 50 mM HEPES-Na
+
 buffer (pH 7.25). For the determination 
of substrate kinetic parameters, the αKG concentration was held constant at 10 mM while the 
specified substrate concentration ranged from 0-2.5 mM. For the determination of KM with αKG, 
the FR-900098 concentration was held constant at 1 mM while the final concentration of αKG 
ranged from 0-10 mM. All reactions were initiated by the addition of recombinant FrbJ and run 
at 25°C. Aliquots were taken and quenched by the addition of 4% trifluoroacetic acid and were 
kept at 4°C until analysis by HPLC. The kinetic parameters were obtained after measuring the 
extracted ion chromatograms of product formation from LC-MS analysis. 
 
4.5.4 LC-MS Analysis 
 
 Products of the enzymatic reactions were analyzed by an Agilent 1100 series LC/MSD 
XCT plus ion trap mass spectrometer (Agilent, Palo Alto, CA) at the Roy J. Carver 
Metabolomics Center at the University of Illinois (Urbana, IL).  The liquid chromatography (LC) 
was performed using an Agilent 1100 series HPLC equipped with an online degasser, binary 
pump, and autosampler.  The mass spectrometry (MS) was performed using an Agilent XCT ion 
trap MSD mass spectrometer.  The MS system was operated using a drying temperature of 
350°C, a nebulizer pressure of 35 psi, a drying gas flow of 8.5 L min
-1
, and a capillary voltage of 
4500 V.  For the CMP-containing compounds, analytes were resolved on a 150 × 4.6 mm C18 
reverse-phase HPLC column (Agilent, Palo Alto, CA).  HPLC parameters were as follows: 
solvent A: 15 mM ammonium formate; solvent B: 20 mM ammonium acetate; 25% solvent B at 
0 minutes; gradient 100% solvent B in 10 minutes, and 100% solvent B for 3 minutes; flow rate: 
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0.3 mL min
-1
; detection by UV absorbance at 254 nm.  Mass spectra were acquired in ultra scan 
mode using electrospray ionization (ESI) with negative polarity.  For the non-CMP-containing 
compounds, analytes were resolved on a 100 x 4.6 mm Synergi 4u Fusion-RP 80A analytical 
column (Phenomenex, Torrance, CA).  HPLC parameters were as follows: solvent A: 0.1% 
formic acid in ddH2O; solvent B: 100% acetonitrile; gradient of 0 to 40% solvent B for 10 
minutes, a gradient of 40 to 100% solvent B for 3 minutes, and 100% solvent B for 5 minutes; 
flow rate of 200 µL min
-1
.  Mass spectra were acquired in ultra scan mode using electrospray 
ionization with positive polarity. 
 
4.5.5 Antimalarial Library Creation 
 
 Overexpression strains for DhpI and Pfs (SAH nucleosidase from E. coli) were obtained 
from Dr. Jin-Hee Lee in Professor Wilfred van der Donk’s laboratory. Both constructs contained 
His6-tags making them amenable to purification by IMAC coupled to FPLC as described in 
Section 4.5.2. Commercially available FR-900098 and fosmidomycin were the starting substrates 
for the antimalarial library. These two compounds (5 mM) were incubated with 25 μM purified 
FrbJ and 10 mM αKG, 200 μM Fe(II)SO4, and 800 μM ascorbic acid. Reaction mixtures were 
kept at 25°C for 24 hours to ensure complete conversion to products. Samples were then 
transferred into a Microcon
®
 centrifugal filter device (MWCO 10,000) and centrifuged for 10 
minutes at maximum speed to remove enzyme, yielding solutions of FR-33289 and 
hydroxyfosmidomycin. These hydroxylated samples, FR-900098, and fosmidomycin were then 
used as substrates for the second in vitro reaction. These four compounds (5 mM) were incubated 
with 25 μM purified DhpI, 25 μM purified Pfs, and 10 mM SAM at 25°C for 24 hours. Once 
again, samples were then transferred into a Microcon® centrifugal filter device (MWCO 10,000) 
and centrifuged for 10 minutes at maximum speed to remove enzyme, yielding solutions of O-
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methylated phosphonates. The prospective antimalarial library was then purified using LC-MS 
method similar to that described in Section 4.5.4. Fractions were collected and then checked for 
purity before final lyophilization to dryness. 
 
4.5.6 Bioauthentication by E. coli Bioassay 
 
 The E. coli bioassay strain WM6242 contains three component phosphonate uptake genes 
phnCDE integrated into the λ and HK sites of the chromosome, each of which are under an IPTG 
inducible Ptac promoter
13
. Expression of these three genes creates a hypersensitive E. coli strain 
to phosphonate antibiotics. FR-900098-sensitive strain HZ832 is WM6242 transformed with 
pETDuet, pRSFDuet, and pACYCDuet to ensure ampicillin, kanamycin, and chloramphenicol 
resistance, respectively. Although not required in the assays described here, inclusion of these 
plasmids protects against any background antimicrobial activity in the spent media of E. coli FR-
900098 production strains. FR-900098-resistant strains HZ1015 and HZ1016 were created by 
transforming WM6242 with pMal-c2x-dxrB and pMal-c2x-ispC (cloned under Ptac promoter 
without maltose binding protein fusion), respectively, in addition to pRSFDuet and pACYCDuet. 
Overnight cultures of the three strains were grown in LB media with the following antibiotic 
concentrations: ampicillin, 50 µg mL
-1
; kanamycin, 25 µg mL
-1
; and chloramphenicol, 12.5 µg 
mL
-1
. Saturated overnight cultures were diluted 10-fold in LB media and 100 µL was mixed with 
3 mL of 1.0% top agar. The mixture was spread on Antibiotic 2 media + 0.4 mM IPTG plates 
and allowed to solidify. Blank paper discs were impregnated with sample and incubated 
overnight at 37°C, after which they were analyzed for zones of inhibition growth. 
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4.5.7 Bioauthentication by pfDxr Inhibition 
 
 The full-length dxr gene from Plasmodium falciparum was codon-optimized for 
expression in E. coli by DNA 2.0 (Menlo Park, CA). The corresponding 72 amino acid long 
signal peptide was removed by Ryan Cobb to increase soluble expression
37-38
. An N-His6-tag 
was introduced to the shortened protein making it amenable to purification by IMAC coupled to 
FPLC as described in Section 4.5.2. The inhibition of the enzymatic activity of pfDxr was 
determined in triplicate at 25°C. Each reaction mixture (300 µL final volume) contained 50 nM 
pfDxr, 300 μM NADPH, 1 mM MnCl2 in 50 mM HEPES-Na
+
 buffer (pH 7.25). The reaction 
was monitored by NADPH oxidation at 340 nm. For the determination of IC50 values, substrate 
concentration was held at 250 µM and inhibitor concentrations of 0-500 nM were used. For the 
determination of KI values, substrate concentration ranged from 0-250 µM and inhibitor 
concentrations of 0-100 nM were used. 
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Chapter 5: Metabolic Engineering to Increase FR-900098 
Production in E. coli 
 
 
5.1 Introduction 
 
 The current production level of the antimalarial FR-900098 in the heterologous host 
Escherichia coli was measured to be 6.3 mg L
-1
. This strain was created by Dr. Tyler Johannes; 
each gene (except frbI and frbJ) was under the transcriptional control of a strong T7 promoter on 
three compatible Duet expression vectors
1
. Metabolic engineering will now be utilized in order 
to increase production of FR-900098 in efforts to reach the ultimate goal of 1 g L
-1
. Two 
approaches will be taken towards meeting this objective: (1) pathway engineering to optimize the 
overall metabolic flux through the FR-900098 biosynthetic pathway and (2) host engineering to 
create a heterologous E. coli strain which overproduces phosphoenolpyruvate (PEP). 
  Metabolic flux analysis was performed on our current heterologous production strain. 
Each of the intermediates in FR-900098 biosynthesis was monitored over a period of 48 hours 
post-induction by liquid chromatography-mass spectrometry (LC-MS). Nearly all of the 
intermediates began to build up corresponding to the eventual plateau in FR-900098 production 
seen after approximately 30-35 hours (Figure 2.2B). Severe metabolic burden is being placed on 
the E. coli production strain from the T7 overexpression of the nine Streptomyces genes resulting 
in a far from optimized metabolic flux and a need for further engineering. Pathway engineering 
to maximize the overall flux in FR-900098 biosynthesis will be specifically accomplished 
through ribosome binding site (rbs) engineering. The rbs is a short mRNA sequence that affects 
the frequency of translation initiation and thereby the expression level of the gene
2
. This 
sequence, referred to as the Shine-Dalgarno (SD) sequence in prokaryotes (AAGGAG)
3
, is 6 
bases long and is typically 6-8 bases upstream of the ATG start codon of the gene. The AG-rich 
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rbs sequence is highly conserved and point mutations have been shown to have drastic effects on 
the gene expression
4
. This chapter will describe the development of an rbs engineering platform 
which utilizes green fluorescent protein (GFP) as a reporter of gene expression. A library of rbs 
strengths will be created by mutagenesis of the SD sequence, which can then be transferred to 
the FR-900098 biosynthetic genes for an increased metabolic flux through the pathway and 
improved production of the antimalarial.  
 The second approach to increase production of FR-900098 is similar in theory to the first, 
except the metabolic flux in the entire E. coli host is adjusted to increase the amount of available 
PEP and thus channel more flux into the biosynthetic pathway. PEP, the common precursor of all 
known phosphonates, is also involved in several primary metabolic pathways (Figure 5.1). In 
particular, the compound is the phosphoryl group donor in the cellular uptake of glucose through 
the phosphotranferase system (PTS), first discovered in 1964
5
. PEP also undergoes 
interconversions with other key metabolites; pyruvate through the enzymes PEP synthase (Pps) 
and pyruvate kinase-I and -II (isozymes PykFA) and oxaloacetate through the enzymes Pck (PEP 
carboxykinase) and Ppc (PEP carboxylase). Targeted manipulation of these pathways involving 
PEP should be able to channel flux into the FR-900098 biosynthetic pathway and increase the 
production of FR-900098. This chapter will describe the host engineering of E. coli to 
overexpress the enzymes Pps and Pck in order to increase the available pool of PEP within the 
cell. Also, a global regulatory protein CsrA, which represses formation of Pps and Pck while 
activating PykF, will be targeted for deletion from the chromosome of the heterologous 
production host. 
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Figure 5.1 Pathways involved in primary metabolism which involve the metabolite phoshoenolpyruvate 
and subsequently phosphonates like FR-900098. Tan, glycolysis pathway; Blue: TCA cycle. G6P, 
glucose-6-phosphate; PEP, phosphoenolpyruvate; Pyr, pyruvate; AcCoA, acetyl coenzyme A; OAA, 
oxaloacetate; Pps, PEP synthase; PykFA, pyruvate kinases I and II; Ppc, PEP carboxylase; Pck, PEP 
carboxykinase. 
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5.2 Results 
 
5.2.1 Design and Construction of GFP Reporter Plasmids 
 
 Pathway engineering of a single gene pathway has been worked on extensively with 
numerous successful examples. However, engineering of a multi-gene pathway contains a much 
higher level of complexity, since each of the genes likely will require a different expression 
level
6
. As a result, simultaneous modifications to the entire pathway must be made to access the 
full potential and achieve the best results. Several methods have been created for the assembly of 
large DNA molecules with high efficiency, a necessary tool for engineering of a multi-gene 
pathway
7-9. Dr. Zengyi Shao has recently developed a highly efficient approach named “DNA 
assembler” which allows for the rapid construction of large constructs, including biosynthetic 
pathways, in a single step via in vivo homologous recombination in Saccharomyces cerevisiae
10
. 
This highly versatile system will be used throughout the development of a new platform for 
efficient rbs engineering. 
 Our current E. coli production strain contains each FR-900098 biosynthetic gene under 
the transcriptional control of a single strength rbs. In order to introduce diversity, a library of rbs 
variants with varying strengths will be generated by randomly mutagenizing the 6 base sequence. 
However, the current production system will not successfully translate to the proposed approach 
with DNA assembler, which relies on regions of homology to overlap and thereby recombine. 
The promoter region itself (100-150 bases) will remain largely intact while only the short rbs 
sequence will differ from clone to clone. Implementation of DNA assembler with a library of 
only T7 promoters will ultimately result in gene deletions, since the regions of homology from 
the nearly identical promoters will be large enough leading to additional, undesirable 
recombinations. As a result, four different promoters will be utilized for rbs engineering: Lac, 
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T7, Tac, and Trc. All are inducible by isopropyl-β-D-thiogalactopyranoside (IPTG), meaning 
growth and media conditions remain identical to our current production system. 
 Green fluorescent protein (GFP) will be used as a reporter of gene expression in order to 
generate the library of rbs variants with varying strengths. A set of four plasmids was first 
constructed via DNA assembler, one for each promoter of interest (Figure 5.2). The GFP reporter 
plasmid consists of five individual parts which were separately amplified by PCR: promoter, 
GFP gene, terminator, S. cerevisiae helper fragment, and E. coli helper fragment. The 5’ end of 
each fragment was designed to overlap with the previous, while the 3’ end was designed to 
overlap with the next. Each successive DNA fragment is designed to share homology with the 
two flanking ones by an 80 base overlap. For example, the forward primer for the amplification 
of GFP contained sequence homology to the end of the promoter and the reverse primer 
contained sequence homology to the beginning of the terminator. The S. cerevisiae helper 
fragment contained the ura3 gene for selection and CEN/ARS origin of replication (cloned from 
pRS416). Similarly, the E. coli fragment contained a Kan
R
 gene for selection and RSF origin of 
replication (cloned from pRSFDuet). S. cerevisiae were transformed with the linear PCR 
products and grown on plates of synthetic drop-out media lacking uracil (SC-Ura). Yeast 
colonies were randomly picked and the assembled circular plasmids were subsequently purified. 
Due to typically low quality and quantity, the isolated yeast plasmids were transformed into E. 
coli and selected on LB+Kan plates. Further verification and manipulation steps were performed 
with plasmids isolated from E. coli. Each of the four plasmids were subjected to and confirmed 
by restriction digestion.  
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Figure 5.2 Example of GFP reporter plasmid, pMD-Lac-GFP. The S. cerevisiae helper fragment 
contained the ura3 gene for selection and CEN/ARS origin of replication. Similarly, the E. coli fragment 
contained a Kan
R
 gene for selection and RSF origin of replication. 
 
 Several additional features were added to the GFP reporter plasmids; all of which were 
included in the primer design. An EcoRI restriction site was included between the E. coli 
fragment and promoter and a NheI restriction site was included immediately after the TGA stop 
codon of the GFP gene. Also, the 6 bases immediately before the ATG start codon of the GFP 
gene (between the rbs sequence and ATG) were replaced with an AflII restriction site. Inclusion 
of the EcoRI and AflII sites allowed for the amplification and screening of the rbs library by GFP 
fluorescence. These restriction sites were specifically chosen since they do not cut anywhere else 
on the plasmid, including the GFP gene. Inclusion of the AflII and NheI sites allowed for the 
removal of the GFP gene and replacement with any FR-900098 biosynthetic gene. Similarly, 
neither of these sites cut anywhere else on the plasmid or any of the biosynthetic genes.  
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Figure 5.3 Activity of four GFP reporter plasmids was monitored by UV fluorescence after induction by 
IPTG. Negative control (pET26b) demonstrated no fluorescence while four reporters were active. 
 
 E. coli BL21(DE3) cells were transformed with the four reporter plasmids and GFP 
expression was induced by the addition of IPTG. All four contained active GFP reporter 
constructs as demonstrated by UV fluorescence (Figure 5.3). The comparative strength of the T7 
promoter was easily observed as the cells turned green from GFP expression, whereas no cell 
color change was observed for the Lac, Tac, and Trc constructs. 
 
5.2.2 Formation of GFP Library 
 
 Randomized mutagenesis was used to generate a library of rbs variants with varying 
strengths for each of the four promoters. Primers were designed to replace each nucleotide in the 
existing AG-rich rbs sequence with nonspecific “N” nucleotide (Table 5.1). The promoter was 
amplified for each using the mutagenesis primers, digested with EcoRI and AflII, and ligated 
back into the corresponding GFP reporter vector. E. coli BL21(DE3) cells were transformed with 
the rbs library, induced with ITPG, and screened by flow cytometry. 
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Table 5.1 Primer sequences used in the rbs library generation. Mutagenesis of the rbs sequence is shown 
in bold. AflII restriction site is shown by underlining and italics. 
 
Oligonucleotide  DNA sequence (5'3') 
Lac mutant promoter CGAAATATCTTAAG NNNNNN GTGTGAAATTGTTATCCGCT 
T7 mutant promoter CGAAATATCTTAAGAT NNNNNN CTTAAAGTTAAACAAAATTA 
Tac mutant promoter CGAAATATCTTAAGTGG NNNNN GTTGGTGAAGTGCTCGTGAA 
Trc mutant promoter CGAAATATCTTAAG NNNNNN GTGTGAAATTGTTATCCGCT 
  
 GFP fluorescence of the mutagenized rbs library was assessed in comparison to the wild 
type rbs by flow cytometry (Figure 5.4). Fluorescence signal above the pET26b negative control 
was clearly observed for each of the four wild type rbs constructs. However, GFP fluorescence 
was abolished and aligned with the negative control for each of the rbs mutant libraries. 
Randomization of the full rbs sequence predominantly created inactive clones, and a majority of 
the AG-rich sequence must be retained in order for moderate amounts of translation initiation. 
 
  
Figure 5.4 Analysis of GFP expression in pET26 (negative control), pMD-Lac-GFP (wild type rbs), and 
mutagenized rbs library of pMD-Lac-GFP by flow cytometry. Randomized rbs library abolished activity 
as seen by profile alignment with negative control. 
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5.2.3 Construction of Full FR-900098 Pathway 
 
 The final assembled FR-900098 pathway would be split into two plasmids, one 
containing the early steps of synthesis (frbD, frbC, frbA, and frbB) and the other contained the 
late steps of synthesis (frbE, frbH, frbG, and frbF). Each plasmid would contain one of the four 
promoters; for example, T7-frbD, Tac-frbC, Lac-frbA, and Trc-frbB. Recombination events in E. 
coli occur at a far less frequent rate in comparison to S. cerevisiae, so the eventual 
cotransformation of the two final plasmids will not cause any undesired gene deletions. The GFP 
gene was replaced from each of the four initial reporter plasmids with one of the FR-900098 
biosynthetic genes. The engineered restriction sites AflII and NheI were utilized to digest and 
ligate in the desired genes, forming a set of eight intermediate plasmids (Figure 5.5). 
 
  
 
Figure 5.5 Example of FR-900098 gene intermediate, pMD-Lac-frbA. The GFP gene was removed from 
pMD-Lac-GFP (seen in Figure 5.2) by digestion of the AflII and NheI restriction sites. The frbA gene was 
amplified with identical flanking sites and ligated in the digested vector to form this plasmid. 
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 The full gene cassette containing the corresponding promoter and terminator was 
amplified from the eight intermediate plasmids. Each cassette had homology to the flanking 
cassette (or helper fragment). The regions of homology used in the in vivo yeast homologous 
recombination are non-specific; although the order of promoters is set (Trc-T7-Lac-Tac), they 
are not dependent on the FR-900098 biosynthetic gene or mutagenized rbs sequence. This design 
is ideal for library creation in that it will not rely on excessive amount of primers for assembly of 
the final plasmid libraries. 
 Assembly of the final two plasmid system was completed as a proof of concept similar 
the original GFP reporter plasmid (Figure 5.6). Each plasmid contained four FR-9000989 gene 
cassettes, an E. coli helper fragment, and a S. cerevisiae helper fragment. In an effort to reduce 
metabolic burden on the cell, the origins of replications of the two plasmids with the lowest copy 
number from the Duet expression system were chosen, CDF (from pCDFDuet) with 20-40 
copies and P15A (from pACYCDuet) with 10-12 copies. Once again, fully assembled plasmids 
were isolated from E. coli and subjected to and confirmed by restriction digestion. However, 
cotransformation of the two plasmid harboring the full pathway in E. coli BL21(DE3) and 
subsequent protein induction by IPTG did not produce any FR-900098. Experiments are 
currently ongoing to ensure presence of mRNA for the FR-900098 biosynthetic genes within the 
cell by qPCR. 
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Figure 5.6 Example of the final compatible two plasmids harboring the full FR-900098 biosynthetic 
pathway. Each biosynthetic gene is under the transcriptional control of an IPTG-inducible promoter. 
Plasmids pMD2 and pMD3 are identical to pMD4 and pMD1, respectively, except the E. coli fragments 
are swapped. 
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5.2.4 Pck and Pps Overexpression 
 
 Host engineering of E. coli was accomplished by the targeted manipulation of the 
primary metabolic pathways involving PEP. As seen in Figure 5.1, PEP is the product of the 
reactions catalyzed by PEP carboxykinase (Pck) and PEP synthase (Pps). Overexpression of 
these genes should be able to channel flux into the FR-900098 biosynthetic pathway and increase 
the production of FR-900098. The Liao laboratory reported the overxpression of both genes, 
which were successful in redirecting carbon flux away either back up the glycotic pathway or out 
of the TCA cycle to increase the intracellular level of PEP. They sought to increase lycopene 
biosynthesis which uses glyceraldehyde 3-phosphate (G3P), an immediate precursor of PEP. 
Overexpression of pps increased the final titer of lycopene 5-fold, whereas ovexpression of pck 
increased the final titer 3-fold
11
. 
 The genes pck and pps were initially cloned from the E. coli MG1655 genome and ligated 
into pCDFDuet to ensure compatibility with the current production system (HZ960), pETDuet-
frbABCD, pRSFDuet-frbHFG, and pACYCDuet-frbE-dxrB. Similar to the FR-900098 
biosynthetic genes, these two genes were also under the transcriptional control of a strong T7 
promoter. Upon cotransformation with the current system, the now four plasmid production hosts 
were assayed for production of FR-900098 by LC-MS. After 24 hours post-induction, there was 
~30-40% decrease in yield of the final product upon overexpression of pck or pps. Cell-free 
lysate of E. coli BL21(DE3) strains expressing only pCDFDuet-pck or pCDFDuet-pps were 
assayed by SDS-PAGE. Overexpression of these native E. coli genes by the strong T7 promoter 
accounted for ~90% of the total soluble protein within the cell. The amount of cellular resources 
used in protein expression of pck or pps far outweighed any increases of PEP within the cell, 
resulting in the drastic decrease in FR-900098 production. 
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 In order to reduce the metabolic burden caused by overexpressing the E. coli genes under 
the strong T7 promoter, we switched to expression by the weaker Tac promoters. In order to 
remain compatible with the current production system, the plasmid pMD-Tac-GFP was used as 
the plasmid backbone for further modifications. The GFP gene was replaced with either pck or 
pps, and the E. coli helper fragment consisting of the RSF origin of replication and Kan
R
 gene 
(both from pRSFDuet) was replaced with the CDF origin of replication and Sm
R
 gene (both from 
pCDFDuet). Similar to the prior case, the new four plasmid system was cotransformed and 
assayed for FR-900098 production by LC-MS. Although there was an increase in production 
between overexpression by the weaker Tac promoter as compared to the stronger T7 promoter, 
there was still a significant decrease in FR-900098 production in the existing E. coli strain 
(Figure 5.7). 
 
 
 
Figure 5.7 Comparison of FR-900098 production from the current E. coli strain (pETDuet-frbABCD, 
pRSFDuet-frbHFG, pACYCDuet-frbE-dxrB; HZ960) alone and with the inclusion of pck or pps 
overexpression under T7 and Tac promoters. 
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5.2.5 CsrA Deletion 
 
 The short 186 basepair gene csrA encodes a protein that is very important to carbon 
metabolism within the cell, binding to at least 25 specific mRNA molecules. This global 
regulatory protein represses formation of Pck and Pps while activating PykF. Disruption of this 
gene in E. coli increases the level of PEP
12
 and may lead to improved FR-900098 production. 
Initial attempts at complete deletion of this gene via the λ Red recombinase system13 were 
unsuccessful as the cells were very sick and specific transformants were never able to be 
obtained, a clear indication as to the importance of this protein to carbon metabolism. E. coli 
strain TRMG1655 (csrA::Kan) was kindly provided by Professor Tony Romeo at the University 
of Florida. This strain has a transposon insertion towards the end of the gene which leaves some 
activity within the cell
14
. P1 transduction was performed to move the transposon in csrA from 
this donor strain to E. coli BL21(DE3)
15
. 
  Due to the selectable kanamycin resistance marker within the transposon, the current FR-
900098 production system was no longer compatible due to the Kan
R
 gene on pRSFDuet. As a 
result, the frbHFG cassette was moved from pRSFDuet to pCDFDuet, yielding pCDFDuet-
frbHFG. The plasmids pETDuet-frbABCD, pACYCDuet-frbE-dxrB, and pCDFDuet-frbHFG 
were cotransformed in E. coli strains BL21(DE3) and BL21(DE3) csrA::Kan. These two new 
production strains were then assayed for FR-900098 production by LC-MS (Figure 5.8). Once 
again, there was a noticeable decrease in the E. coli strain designed to increase the PEP levels. 
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Figure 5.8 Comparison of FR-900098 production from strains E. coli BL21(DE3) and E. coli BL21(DE3) 
csrA::Kan. The latter was created via P1 transduction of the transposon from TRMG1655. Both E. coli 
production strains contained the expression plasmids pETDuet-frbABCD, pACYCDuet-frbE-dxrB, and 
pCDFDuet-frbHFG. 
 
 
5.3 Discussion 
 
 The recent attempts at the host engineering of E. coli revealed key insights for future 
efforts in metabolic engineering. Most importantly, the decrease in FR-900098 production 
observed with the overexpression of pck and pps and the transposon insertion in csrA 
demonstrate that the problems lie in the pathway flux rather than a deficiency in PEP. This issue 
was illustrated in the development of the newest production strain compared to the previous one 
from Dr. Tyler Johannes. As previously mentioned, the frbHFG cassette was moved from the 
highest copy number Duet expression plasmid pRSFDuet (copy number >100) to the lower 
pCDFDuet (copy number 20-40), while the other plasmids (pETDuet-frbABCD and 
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pACYCDuet-frbE-dxrB) remained constant. After 24 hours post-induction, there was ~50% 
higher production in the E. coli strain containing the lower copy number plasmid (5.9 mg L
-1
 vs. 
4.0 mg L
-1
). Expression of a multi-gene pathway from the high GC-content Streptomyces places 
a steep metabolic burden on the heterologous host based on the sheer number of expressed genes 
as well the rare codon usage present in them. Reduction of the copy number appeared to help in 
this case; however, a clear balance remains between “weak” and “too weak”. The strong T7 
promoter remained in both production strains, while expression of the FR-900098 biosynthetic 
genes under the weaker Lac, Tac, and Trc promoters resulted in an inactive pathway. 
 
 
5.4 Conclusions and Outlook 
 
 Metabolic flux analysis of intermediates present in the late steps of FR-900098 
biosynthesis revealed a serious problem. A build up of all nucleotide conjugated intermediates 
without the required CMP was observed in the production strain. FrbI has always been excluded 
from our production strains, instead relying on ubiquitous nucleotide hydrolases to cleave CMP-
5’-FR-900098 to the final product. Besides using additional cellular resources, expression of FrbI 
only worsens the problem by increasing the rate of CMP cleavage from the intermediates even 
more. These compounds, some of which possess bioactivity, are unable to be recovered by 
reattachment via FrbH and build up in the cell. The ubiquitous E. coli enzymes, while useful in 
their ability to produce the final product, will create unreactive side products at the same time. 
Deletion of these from the genome and supplementation with the more specific nucleotide 
hydrolase FrbI could produce detrimental and potentially deadly results in E. coli. 
 While the efforts described in this chapter did not show improvements in FR-900098 
production, the strains and platforms developed here still hold great promise. The rbs 
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engineering platform coupled with our DNA assembler method remains a potential choice for 
other multi-gene pathways. The primers used to create the mutagenic library could be redesigned 
to include more of the original AG-rich sequence instead of completely randomizing it, ensuring 
the isolation of clones with moderate levels of GFP fluorescence. Also, the engineered E. coli 
strains designed to increase the level of PEP can first be verified for higher concentrations of the 
metabolite as described elsewhere
16
. These strains could then be used for other phosphonate 
biosyntheses which already have undergone pathway optimization. 
 
 
5.5 Materials and Methods 
 
5.5.1 Materials 
 
 Escherichia coli strain TRMG1655 (csrA::Kan) was kindly provided by Professor Tony 
Romeo at the University of Florida (Gainesville, FL). E. coli BL21(DE3) was purchased from 
Novagen (Madison, WI). E. coli wild type strain MG1655 as kindly provided by Professor 
Christopher Rao at the University of Illinois (Urbana, IL). Strain HZ848 is Saccharomyces 
cerevisiae strain YSG50 with a deletion of ura3 instead of point mutation created by Dr. Nikhil 
Nair. Oligonucleotide primers were obtained from Integrated DNA Technologies (Coralville, 
IA). Phusion
®
 High-Fidelity DNA polymerase, antarctic phosphatase, T4 DNA ligase, all 
restriction enzymes, and protein size markers were purchased from New England Biolabs (NEB) 
(Beverly, MA). PCRs were performed with FailSafe
™
 PCR PreMix buffer G from Epicentre 
Biotechnologies (Madison, WI). The QIAprep spin plasmid miniprep kit and QIAquick gel 
extraction kit were purchased from Qiagen (Valencia, CA). The Zymoprep Yeast Plasmid 
Miniprep II kit was purchased from Zymo Research (Irvine, CA). CSM-URA media was 
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purchased from MP Biomedicals (Solon, OH). SDS-PAGE gel materials, electrophoresis 
equipment, and size exclusion standards were purchased from Bio-Rad (Hercules, CA). 
 
5.5.2 Construction of GFP Reporter Plasmids 
 
 Each GFP reporter plasmid consisted of five individual parts which were separately 
amplified by PCR: promoter, GFP gene, terminator, S. cerevisiae helper fragment, and E. coli 
helper fragment. Promoter and terminators for each plasmid were amplified from the following 
source: Lac, pUC19; T7, pET26b; Tac, pMAL-c2x; Trc, pTrc99a. E. coli helper fragment was 
amplified from pRSFDuet, S. cerevisiae helper fragment from pRS416, and GFP from pRS426-
GFP (Table 5.2). All primers contained homology to flanking fragment, except yeast which was 
unable to be amplified otherwise (Table 5.3). 
 
Table 5.2 Plasmids and strains used in the assembly of GFP promoter reporters. 
 
Plasmid or strain Description Source or reference 
   
Plasmids   
  pUC19 E. coli vector, Lac promoter, Amp
R
 Invitrogen 
  pET26b E. coli vector, T7 promoter, Kan
R
  Novagen 
  pMAL-c2x E. coli vector, Tac promoter, Amp
R
 NEB 
  pTrc99a E. coli vector, Trc promoter, Amp
R
  Amersham Pharmacia 
  pRS416 E. coli / S. cerevisiae vector, Amp
R
, ura3 NEB 
  pRSFDuet     E. coli vector, RSF ori, Kan
R
   Novagen 
  pRS426-GFP GFP in a pRS426 background  Dr. Zengyi Shao 
  pMD-Lac-GFP GFP under Lac promoter, Kan
R
 This study 
  pMD-T7-GFP GFP under T7 promoter, Kan
R
 This study 
  pMD-Tac-GFP GFP under Tac promoter, Kan
R
 This study 
  pMD-Trc-GFP GFP under Trc promoter, Kan
R
 This study 
   
Strains   
  E. coli BL21(DE3) F
-
 ompT gal dcm hsdSβ(rβ
-
 mβ
-
) λ(DE3) Novagen 
  S. cerevisiae HZ848 MATα ade2-1 ade3Δ22 Δura3 his3-11,15 
trp1-1 leu2-3,112 can1-100 
Dr. Nikhil Nair 
  HZ3382 BL21(DE3) with pMD-Lac-GFP This study 
  HZ3383 BL21(DE3) with pMD-T7-GFP This study 
  HZ3384 BL21(DE3) with pMD-Tac-GFP This study 
  HZ3385 BL21(DE3) with pMD-Trc-GFP This study 
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Table 5.3 Primer sequences used in the assembly of GFP promoter reporters. 
 
Oligonucleotide
  
DNA sequence (5'3') 
yeast for CGAAAAGTGCCACCTGGGTCCTTTT 
yeast rev GTGAGTTTAGTATACATGCATTTAC 
E. coli for AAAACTGTATTATAAGTAAATGCATGTATACTAAACTCACAAACCAGCAATAGACATAAG 
Lac E. coli rev  GAGTGAGCTAACTCACATTAATTGCGTTGCGCTCGAATTCGCGCAACGCAATTAATGTAA 
Lac promoter for ATGAGTGAGCTAACTTACATTAATTGCGTTGCGCGAATTCGAGCGCAACGCAATTAATGT 
Lac promoter rev CAACTCCAGTGAAAAGTTCTTCTCCTTTACTCATCTTAAGTTTCCTGTGTGAAATTGTTA 
Lac GFP for GAATTGTGAGCGGATAACAATTTCACACAGGAAACTTAAGATGAGTAAAGGAGAAGAACT 
Lac GFP rev CAGCGGGTGTTGGCGGGTGTCGGGGCTGGCTTAAGCTAGCTCATTTGTATAGTTCATCCA 
Lac terminator for GATTACACATGGCATGGATGAACTATACAAATGAGCTAGCATAAGCCAGCCCCGACACCC 
Lac terminator rev TTATAGCACGTGATGAAAAGGACCCAGGTGGCACTTTTCGAAACAAATAGGGGTTCCGCG 
T7 E. coli rev  AGTGAGTCGTATTAATTTCGCGGGATCGAGATCTGAATTCGCGCAACGCAATTAATGTAA 
T7 promoter for ATGAGTGAGCTAACTTACATTAATTGCGTTGCGCGAATTCAGATCTCGATCCCGCGAAAT  
T7 promoter rev ACTCCAGTGAAAAGTTCTTCTCCTTTACTCATCTTAAGATCTCCTTCTTAAAGTTAAACA 
T7 GFP for TAGAAATAATTTTGTTTAACTTTAAGAAGGAGATCTTAAGATGAGTAAAGGAGAAGAACT 
T7 GFP rev CAGCTTCCTTTCGGGCTTTGTTAGCAGCCGGATCGCTAGCTCATTTGTATAGTTCATCCA 
T7 terminator for GATTACACATGGCATGGATGAACTATACAAATGAGCTAGCGATCCGGCTGCTAACAAAGC 
T7 terminator rev TTATAGCACGTGATGAAAAGGACCCAGGTGGCACTTTTCGGATATAGTTCCTCCTTTCAG 
Tac E. coli rev  ATGATTAATTGTCAACAGCTCATTTCAGAATATTGAATTCGCGCAACGCAATTAATGTAA 
Tac promoter for ATGAGTGAGCTAACTTACATTAATTGCGTTGCGCGAATTCAATATTCTGAAATGAGCTGT 
Tac promoter rev CAACTCCAGTGAAAAGTTCTTCTCCTTTACTCATCTTAAGTGGTCCTTGTTGGTGAAGTG 
Tac GFP for GGTGTTTTCACGAGCACTTCACCAACAAGGACCACTTAAGATGAGTAAAGGAGAAGAACT 
Tac GFP rev CTGATTTAATCTGTATCAGGCTGAAAATCTTATCGCTAGCTCATTTGTATAGTTCATCCA 
Tac terminator for GATTACACATGGCATGGATGAACTATACAAATGAGCTAGCGATAAGATTTTCAGCCTGAT 
Tac terminator rev TTATAGCACGTGATGAAAAGGACCCAGGTGGCACTTTTCGACAAACAACAGATAAAACGA 
Trc E. coli rev  TGATTAATTGTCAACAGCTCATTTCAGAATATTTGAATTCGCGCAACGCAATTAATGTAA 
Trc promoter for ATGAGTGAGCTAACTTACATTAATTGCGTTGCGCGAATTCAAATATTCTGAAATGAGCTG 
Trc promoter rev CAACTCCAGTGAAAAGTTCTTCTCCTTTACTCATCTTAAGTTTCCTGTGTGAAATTGTTA 
Trc GFP for GAATTGTGAGCGGATAACAATTTCACACAGGAAACTTAAGATGAGTAAAGGAGAAGAACT 
Trc GFP rev GGCTGAAAATCTTCTCTCATCCGCCAAAACAGCCGCTAGCTCATTTGTATAGTTCATCCA 
Trc terminator for GATTACACATGGCATGGATGAACTATACAAATGAGCTAGCGGCTGTTTTGGCGGATGAGA 
Trc terminator rev TTATAGCACGTGATGAAAAGGACCCAGGTGGCACTTTTCGTGAGCCTTTCGTTTTATTTG 
 
 
5.5.3 Yeast Transformation 
 
 S. cerevisiae strain HZ848 was grown in YPAD medium (50 mL) at 30°C to OD600~0.8. 
Cells were harvested by centrifugation (5 minutes at 4,000 x g) and resuspended in 25 mL of 
sterile water, followed by another wash with 1 mL 100 mM LiAc, and finally resuspended in 500 
µL of 100 mM LiAc. An aliquot of 50 µL yeast cells was pelleted and resuspended in a 
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transformation mixture consisting of 240 µL PEG (50% w/v), 36 µL 1M LiAc, 50 µL ssDNA (2 
mg mL
-1
), and up to 34 µL DNA fragments (remaining volume comprised of sterile water). The 
mixture was vortexed and incubated at 42°C for 30 minutes. The transformed cells were pelleted, 
resuspended in 1 mL of sterile water, spread on a SC-Ura plate supplemented with 2% glucose, 
and incubated for two days at 30°C until colonies appeared. Colonies were randomly picked and 
grown in SC-Ura liquid media supplemented with 2% glucose and grown for two days, after 
which yeast plasmid was isolated using Zymoprep Yeast Plasmid Miniprep II kit. 
 
5.5.4 Flow Cytometry 
 
 For flow cytometric analysis, E. coli cells were grown at 37°C to OD600~0.7 and then 
induced at 25°C by the addition of isopropyl-β-D-thiogalactopyranoside (IPTG) to a final 
concentration of 0.3 mM. The culture was incubated at 25°C for an additional 18 hours, after 
which the cells were diluted 500-fold in PBS buffer. The cells expressing GFP were analyzed on 
the BD Biosciences LSR II at the Flow Cytometry Facility at the University of Illinois (Urbana, 
IL). A total of 200,000 events were scanned at an event rate of <10,000 second. If event rate was 
higher, the sample was diluted in PBS further until desired event rate was reached. 
 
5.5.5 Construction of Full FR-900098 Pathway 
 
 Each FR-900098 biosynthetic gene was amplified from the original pET26b cloning 
vectors from Dr. Tyler Johannes. The primers contained flanking restriction sites for AflII and 
NheI, which were then used to replace GFP from the reporter plasmids with a corresponding frb 
gene (Table 5.4). 
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Table 5.4 Primer sequences used in the assembly of GFP promoter reporters. Restriction sites shown by 
underlining and italics. 
 
Oligonucleotide  DNA sequence (5'3') 
frbA-for-AflII  GCTATTAATCTTAAGATGCGCGACCTGTTACGGGACC 
frbA-rev-NheI CGAAATATGCTAGCTCAGGCCTCGGCGTCGAGCAGGTCC 
frbB-for-AflII GCTATTAATCTTAAGATGACTGTTTCCCAGTACCCGG 
frbB-rev-NheI CGAAATATGCTAGCTCAGGACCGGGCGGGGCC 
frbC-for-AflII GCTATTAATCTTAAGATGCGCAACGACTTAGTGCTCGAGG 
frbC-rev-NheI CGAAATATGCTAGCTCAGGCGGCGGCCTTGTTGTAGATC 
frbD-for-AflII GCTATTAATCTTAAGATGACCAAGCGAACCATGTTACGCAG 
frbD-rev-NheI CGAAATATGCTAGCTCAGCGCTGGAGCTCGAAGACCTCG 
frbE-for-AflII GCTATTAATCTTAAGATGCGTAAACACACAGTCACTCTGA 
frbE-rev-NheI CGAAATATGCTAGCTCATCCGATGTCCCGCAGGCGCTCG 
frbF-for-AflII GCTATTAATCTTAAGATGATCCGTCACATCGACGCGAGGA 
frbF-rev-NheI CGAAATATGCTAGCTCATGCGCCCACCGCCCGGGCGAGG 
frbG-for-AflII GCTATTAATCTTAAGATGACGCACTACGCGACCGTCATCTG 
frbG-rev-NheI CGAAATATGCTAGCTCAACGCCCATCCTCCGTACGATC 
frbH-for-AflII GCTATTAATCTTAAGATGAACGAGAACCGGACCTTCGCCAC 
frbH-rev-NheI CGAAATATGCTAGCTCAGCCGTCGGCACGGCCCGCCCC 
 
 The full gene cassette containing the promoter, gene, and terminator was amplified from 
the eight intermediate plasmids using the primers in Table 5.5. The full biosynthetic pathway 
was split onto two plasmids; each of which had a set of all four promoters (Table 5.6).  
 
Table 5.5 Primer sequences used in the assembly of full FR-900098 biosynthetic pathway. 
 
Oligonucleotide
  
DNA sequence (5'3') 
yeast for CGAAAAGTGCCACCTGGGTCCTTTT 
yeast rev GTGAGTTTAGTATACATGCATTTAC 
Lac for GGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCGAGCGCAACGCAATTAATGT 
Lac rev  GAGCCGATGATTAATTGTCAACAGCTCATTTCAGAATATTAAACAAATAGGGGTTCCGCG 
T7 for AGTAGGGAACTGCCAGGCATCAAATAAAACGAAAGGCTCAAGATCTCGATCCCGCGAAAT 
T7 rev CCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCGATATAGTTCCTCCTTTCAG 
Tac for GCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTAATATTCTGAAATGAGCTGT 
Tac rev  TGTGCTTCTCAAATGCCTGAGGTTTCAGCAAAAAACCCCTACAAACAACAGATAAAACGA 
Trc for AAAACTGTATTATAAGTAAATGCATGTATACTAAACTCACAAATATTCTGAAATGAGCTG 
Trc rev CCCTATAGTGAGTCGTATTAATTTCGCGGGATCGAGATCTTGAGCCTTTCGTTTTATTTG 
ACYC/CDF for  CAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTAGGGGTTTTTTGCTGAAACC 
ACYC rev TTATAGCACGTGATGAAAAGGACCCAGGTGGCACTTTTCGGGCATGACTAACATGAGAAT 
CDF rev TTATAGCACGTGATGAAAAGGACCCAGGTGGCACTTTTCGGCGCAACGCAATTAATGTAA 
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Table 5.6 Plasmids and strains used in the assembly of full FR-900098 biosynthetic pathway. 
 
Plasmid or strain Description Source or reference 
   
Plasmids   
  pACYCDuet E. coli vector, P15A ori, Cm
R
 Novagen 
  pCDFDuet E. coli vector, CDF ori, Sm
R
  Novagen 
  pRS416 E. coli / S. cerevisiae vector, Amp
R
, ura3 NEB 
  pMD-Lac-frbA frbA under Lac promoter, Kan
R
 This study 
  pMD-Trc-frbB frbB under Trc promoter, Kan
R
 This study 
  pMD-Tac-frbC frbC under Tac promoter, Kan
R
 This study 
  pMD-T7-frbD frbD under T7 promoter, Kan
R
 This study 
  pMD-T7-frbE frbE under T7 promoter, Kan
R
 This study 
  pMD-Trc-frbF frbF under Trc promoter, Kan
R
 This study 
  pMD-Lac-frbG frbG under Lac promoter, Kan
R
 This study 
  pMD-Tac-frbH frbH under Tac promoter, Kan
R
 This study 
  pMD1 frbA, frbB, frbC, frbD under respective 
promoters, P15A ori, Cm
R
 
This study 
  pMD2 frbE, frbF, frbG, frbH under respective 
promoters, P15A ori, Cm
R
 
This study 
  pMD3 frbA, frbB, frbC, frbD under respective 
promoters, CDF ori, Sm
R
 
This study 
  pMD4 frbE, frbF, frbG, frbH under respective 
promoters, CDF ori, Sm
R
 
This study 
   
Strains   
  E. coli BL21(DE3) F
-
 ompT gal dcm hsdSβ(rβ
-
 mβ
-
) λ(DE3) Novagen 
  S. cerevisiae HZ848 MATα ade2-1 ade3Δ22 Δura3 his3-11,15 
trp1-1 leu2-3,112 can1-100 
Dr. Nikhil Nair 
  HZ3382 BL21(DE3) with pMD-Lac-GFP This study 
  HZ3383 BL21(DE3) with pMD-T7-GFP This study 
  HZ3384 BL21(DE3) with pMD-Tac-GFP This study 
  HZ3385 BL21(DE3) with pMD-Trc-GFP This study 
 
 
5.5.6 FR-900098 Biosynthesis 
 
E. coli production strains were grown in Luria-Bertani (LB) medium supplemented with 
the following antibiotic concentrations when necessary: ampicillin, 50 µg mL
-1
; kanamycin, 25 
µg mL
-1
; chloramphenicol, 12.5 µg mL
-1
; streptomycin, 25 µg mL
-1
; and spectinomycin, 25 µg 
mL
-1
. Cells were grown at 37°C to OD600~0.7 and then induced at 30°C by the addition of IPTG 
to a final concentration of 0.3 mM. Samples (1 mL) were then removed from the cultures at 
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specified time points and stored at -80°C. Frozen samples were thawed at room temperature and 
centrifuged at maximum speed for 5 minutes to remove cellular debris. Supernatants from the 
samples were then analyzed by LC-MS. 
 
5.5.7 Cloning of Pck and Pps 
 
The genes for PEP carboxykinase (pck) and PEP synthase (pps) were cloned from the E. 
coli MG1655 genome similar to frbG (Section 3.5.2) and frbJ (Section 4.5.2). Briefly, the genes 
were PCR amplified using primers containing NdeI and HindIII restriction sites and cloned into 
the corresponding sites of pET28a, creating an N-terminal His6-tag.  The primers used for 
cloning of the two genes were: pck-for-NdeI  
5’-GCTATTAATCATATGCGCGTTAACAATGGTTTG-3’, pck-rev-HindIII  
5’-CGAAATATAAGCTTTCACAGTTTCGGACCAGCCGC-3’, pps-for-NdeI  
5’-GCTATTAATCATATGTCCAACAATGGCTCGTCA-3’, and pps-rev-HindIII  
5’-CGAAATATAAGCTTTCATTTCTTCAGTTCAGCCAG-3’, where the corresponding 
restriction sites are underlined and italicized. pck was cloned into the pCDFDuet construct by 
digesting the plasmid pET28a-pck with NcoI and HindIII and cloning the resulting fragment into 
the NcoI/HindIII sites of pCDFDuet to create the construct pCDFDuet-pck. pps was cloned into 
the pCDFDuet construct by digesting the plasmid pET28a-pps with NdeI and XhoI and cloning 
the resulting fragment into the NdeI/XhoI sites of pCDFDuet to create the construct pCDFDuet-
pps (Table 5.7). Plasmids pMD-Tac-pck and pMD-Tac-pps were constructed by PCR amplifying 
the genes using primers containing AflII and NheI restriction sites and cloned into the 
corresponding sites of pMD-Tac-frbC. The Kan
R
 was also replaced with Cm
R
 to ensure 
compatibility with the other plasmids. 
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Table 5.7 Plasmids and strains used in PEP overproduction. 
 
Plasmid or strain Description Source or reference 
   
Plasmids   
  pET28a E. coli vector, T7 promoter, KanR  Novagen 
  pETDuet E. coli Duet vector, ColE1 ori, Ampr  Novagen 
  pRSFDuet E. coli Duet vector, RSF ori, Kmr  Novagen 
  pACYCDuet E. coli Duet vector, P15A ori, Cmr  Novagen 
  pCDFDuet E. coli Duet vector, CDF ori, Smr Novagen 
  pCDFDuet-pck pck under T7 promoter, Smr This study 
  pCDFDuet-pps pps under T7 promoter, Smr This study 
  pMD-Tac-pck pck under Tac promoter, Smr This study 
  pMD-Tac-pps pps under Tac promoter, Smr This study 
  pETDuet-frbABCD frbA, frbB, frbC, and frbD in a pETDuet 
background 
Dr. Tyler Johannes 
  pRSFDuet-frbHFG frbF, frbG, and frbH in a pRSFDuet 
background 
Dr. Tyler Johannes 
  pACYCDuet-frbE-dxrB frbE and dxrB in a pACYCDuet background Dr. Tyler Johannes 
  pCDFDuet-frbHFG frbF, frbG, and frbH in a pCDFDuet 
background 
This study 
   
Strains   
  E. coli BL21(DE3) F- ompT gal dcm hsdSβ(rβ
- mβ
-) λ(DE3) Novagen 
  E. coli MG1655 F- λ- ilvG- rfb-50 rph-1 Dr. Christopher Rao 
  E. coli TRMG1655 F- λ- ilvG- rfb-50 rph-1 csrA::Kan Dr. Tony Romeo 
  HZ3616 BL21(DE3) csrA::Kan This study 
  HZ960 BL21(DE3) with pETDuet-frbABCD, 
pRSFDuet-frbFGH, and pACYCDuet-frbE-
dxrB 
Dr. Tyler Johannes 
  HZ2240 BL21(DE3) with pETDuet-frbABCD, 
pRSFDuet-frbFGH, pACYCDuet-frbE-dxrB, 
and pCDFDuet-pck 
This study 
  HZ3612 BL21(DE3) with pETDuet-frbABCD, 
pRSFDuet-frbFGH, pACYCDuet-frbE-dxrB, 
and pMD-Tac-pck 
This study 
  HZ2241 BL21(DE3) with pETDuet-frbABCD, 
pRSFDuet-frbFGH, pACYCDuet-frbE-dxrB, 
and pCDFDuet-pps 
This study 
  HZ3613 BL21(DE3) with pETDuet-frbABCD, 
pRSFDuet-frbFGH, pACYCDuet-frbE-dxrB, 
and pMD-Tac-pps 
This study 
  HZ3618 BL21(DE3) with pETDuet-frbABCD, 
pCDFDuet-frbFGH, and pACYCDuet-frbE-
dxrB 
This study 
  HZ3619 BL21(DE3) csrA::Kan with pETDuet-
frbABCD, pCDFDuet-frbFGH, and 
pACYCDuet-frbE-dxrB 
This study 
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5.5.8 P1 Transduction 
 
 E. coli TRMG1655 (csrA::Kan) donor cells (1 mL) were grown in Luria-Bertani (LB) 
medium supplemented with kanamycin (50 µg mL
-1
), 0.2% glucose, and 5 mM CaCl2 at 37°C to 
OD600~0.3. Wild type P1vir (1-50 µL) was added to the cells and grown for another 2-3 hours 
until significant lysis occurs as indicated by “clearing” of the culture and decrease in cell density. 
Chloroform (100 µL) was added and the culture was grown for another 10 minutes. The lysed 
culture was centrifuged at 4,000 x g for 5 minutes. The supernatant was then transferred to a 
fresh tube containing 100 µL chloroform and centrifuged again. The cleared supernatant was 
stored overnight at 4°C in a fresh tube containing 100 µL chloroform to ensure complete lysis of 
donor cells. E. coli BL21(DE3) recipient cells (5 mL) were grown to stationary phase, after 
which 5 mM CaCl2 and 10 mM MgCl2 was added. After making 1 mL aliquots, 50-500 µL donor 
P1 lysate was added to the cells, using sterile water as a control. The phages were allowed to 
adsorb to the cells during an incubation for 30-60 minutes at room temperature. Sodium citrate 
was added to a final concentration of 10 mM to sequester the Ca
2+
 ions. The cells were 
centrifuged at 4,000 x g for 5 minutes, resuspended in 1 mL LB supplemented with 10 mM 
sodium citrate, and incubated at 4°C for 1 hour. After two washes with the same supplemented 
medium, the cells were resuspended to 100 µL, spread on a LB plate supplemented with 
kanamycin (50 µg mL
-1
), and incubated overnight at 37°C. 
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